

# Total Body Irradiation and Acute Graft-Versus-Host Disease Damage and Inflammatory Cytokines

Blood

90, 3204-3213

DOI: [10.1182/blood.v90.8.3204](https://doi.org/10.1182/blood.v90.8.3204)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cytokine Dysregulation in Acute Graft-versus-Host Disease. <i>Hematology</i> , 1997, 2, 423-434.	0.7	15
2	Les cytokines: outils et cibles privilégiés dans l'immuno-surveillance du cancer. <i>Annales De L'Institut Pasteur / Actualités</i> , 1998, 9, 121-130.	0.1	0
3	Host Reactive Donor T Cells Are Associated With Lung Injury After Experimental Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1998, 92, 2571-2580.	0.6	114
4	Influence of Intestinal Bacterial Decontamination Using Metronidazole and Ciprofloxacin or Ciprofloxacin Alone on the Development of Acute Graft-Versus-Host Disease After Marrow Transplantation in Patients With Hematologic Malignancies: Final Results and Long-Term Follow-Up of an Open-Label Prospective Randomized Trial. <i>Blood</i> , 1999, 93, 3267-3275.	0.6	248
5	Granulocyte Colony-Stimulating Factor- Mobilized Allogeneic Stem Cell Transplantation Maintains Graft-Versus-Leukemia Effects Through a Perforin-Dependent Pathway While Preventing Graft-Versus-Host Disease. <i>Blood</i> , 1999, 93, 4071-4078.	0.6	108
6	Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft-Versus-Host Disease. <i>Blood</i> , 1999, 94, 825-831.	0.6	168
7	Idiopathic Pneumonia Syndrome after Allogeneic Bone Marrow Transplantation in Mice. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999, 20, 1116-1124.	1.4	46
8	Inability of Activated Cord Blood T Lymphocytes to Perform Th1-like and Th2-like Responses: Implications for Transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 1999, 8, 381-385.	1.8	16
9	New strategies for preventing graft-versus-host disease. <i>Current Opinion in Immunology</i> , 1999, 11, 509-515.	2.4	76
10	Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. <i>Bone Marrow Transplantation</i> , 1999, 23, 151-155.	1.3	41
11	A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999, 23, 1283-1289.	1.3	10
12	Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin. <i>Bone Marrow Transplantation</i> , 1999, 24, 653-659.	1.3	34
13	Pathophysiologic mechanisms of acute graft-vs.-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 347-356.	2.0	317
14	Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 369-378.	2.0	31
15	ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION AS ADOPTIVE IMMUNOTHERAPY. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 1041-1057.	0.9	44
16	Gastrointestinal Manifestations of Graft-versus-Host Disease: Diagnosis and Management. <i>AACN Advanced Critical Care</i> , 1999, 10, 500-506.	1.9	4
17	Graft-versus-host disease: facts and thoughts on recent developments. <i>Current Opinion in Organ Transplantation</i> , 2000, 5, 352-357.	0.8	1
18	CHARACTERIZATION OF GRAFT-VERSUS-HOST DISEASE IN SCID MICE AND PREVENTION BY PHYSICOCHEMICAL STRESSORS. <i>Transplantation</i> , 2000, 70, 1683-1693.	0.5	7

#	ARTICLE	IF	CITATIONS
19	Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. <i>Bone Marrow Transplantation</i> , 2000, 25, 1269-1278.	1.3	226
20	<i>Clostridium difficile</i> infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. <i>Bone Marrow Transplantation</i> , 2000, 26, 871-876.	1.3	122
21	A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 2000, 25, 283-291.	1.3	24
22	Mini-allografts: ongoing trials in humans. <i>Bone Marrow Transplantation</i> , 2000, 25, 345-350.	1.3	204
23	Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. <i>Bone Marrow Transplantation</i> , 2000, 25, S54-S57.	1.3	12
24	Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. <i>British Journal of Haematology</i> , 2000, 111, 18-29.	1.2	6
25	Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: Non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect. <i>Current Oncology Reports</i> , 2000, 2, 132-139.	1.8	19
26	The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. <i>Blood</i> , 2000, 95, 2754-2759.	0.6	643
27	Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis. <i>Blood</i> , 2000, 96, 1836-1843.	0.6	41
28	Hyporesponsiveness of Donor Cells to Lipopolysaccharide Stimulation Reduces the Severity of Experimental Idiopathic Pneumonia Syndrome: Potential Role for a Gut-Lung Axis of Inflammation. <i>Journal of Immunology</i> , 2000, 165, 6612-6619.	0.4	73
29	Pathogenesis of Acute Graft-Versus-Host Disease: Cytokines and Cellular Effectors. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 299-306.	1.8	144
30	Autologous Stem Cell Transplantation As Post-Remission Therapy in Adult Acute Myelogenous Leukemia: Does Platelet Contamination of Peripheral Blood Mobilized Stem Cell Grafts Influence the Risk of Leukemia Relapse?. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 433-443.	1.8	13
31	The p55 TNF- $\alpha$ Receptor Plays a Critical Role in T Cell Alloreactivity. <i>Journal of Immunology</i> , 2000, 164, 656-663.	0.4	130
32	Differential Survival of Naive CD4 and CD8 T Cells. <i>Journal of Immunology</i> , 2000, 165, 3689-3694.	0.4	88
33	Fas-Deficient Mice Are More Susceptible to Graft-Versus-Host Disease. <i>Journal of Immunology</i> , 2000, 164, 469-480.	0.4	70
34	Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease. <i>Cancer Treatment Reviews</i> , 2000, 26, 411-427.	3.4	9
35	Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 434-440.	2.0	71
36	Effect of ursodeoxycholic acid on expression of Fas ligand and tumor necrosis factor-alpha in the liver of mice with acute graft-versus-host disease. <i>Current Therapeutic Research</i> , 2000, 61, 825-836.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Th2 and Tc2 Cells in the Regulation of GVHD, GVL, and Graft Rejection: Considerations for the Allogeneic Transplantation Therapy of Leukemia and Lymphoma. <i>Leukemia and Lymphoma</i> , 2000, 38, 221-234.	0.6	117
38	Genes Highly Expressed in the Early Phase of Murine Graft-versus-Host Reaction. <i>Biochemical and Biophysical Research Communications</i> , 2001, 282, 200-206.	1.0	4
39	Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 136-143.	2.0	27
40	Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 384-387.	2.0	98
41	Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 665-673.	2.0	291
42	Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 352-358.	2.0	35
43	Bone Marrow Cell Graft Engineering: From Bench to Bedside. <i>Leukemia and Lymphoma</i> , 2001, 41, 19-34.	0.6	9
44	Type I Interferon Is the Primary Regulator of Inducible Ly-6C Expression on T Cells. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 621-629.	0.5	29
45	Small Bowel Review: Part II. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2001, 15, 446-466.	1.8	8
46	Interleukin-18 Regulates Acute Graft-Versus-Host Disease by Enhancing Fas-mediated Donor T Cell Apoptosis. <i>Journal of Experimental Medicine</i> , 2001, 194, 1433-1440.	4.2	161
47	Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers. <i>Blood</i> , 2001, 98, 224-230.	0.6	134
48	Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. <i>Blood</i> , 2001, 98, 972-978.	0.6	342
49	Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. <i>Blood</i> , 2001, 98, 2052-2058.	0.6	93
50	Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. <i>Annals of Hematology</i> , 2001, 80, 460-465.	0.8	12
51	Cytokines in Graft-Versus-Host Disease and the Graft-Versus-Leukemia Reaction. <i>International Journal of Hematology</i> , 2001, 74, 26-32.	0.7	32
52	Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. <i>British Journal of Haematology</i> , 2001, 112, 219-227.	1.2	137
53	Introduction to the Series. <i>Scandinavian Journal of Immunology</i> , 2001, 54, 2-3.	1.3	33
54	The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease. <i>Immunology</i> , 2001, 103, 310-318.	2.0	57

#	ARTICLE	IF	CITATIONS
55	Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplantation, 2001, 27, S13-S22.	1.3	32
56	The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transplantation, 2001, 28, 737-742.	1.3	47
57	Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations. Leukemia, 2001, 15, 1967-1975.	3.3	45
58	p53-dependent radiation-induced crypt intestinal epithelial cells apoptosis is mediated in part through TNF-TNFR1 system. Oncogene, 2001, 20, 812-818.	2.6	27
59	Peritoneal B-cell development depends on strain, radiation, and time. Experimental Hematology, 2001, 29, 221-227.	0.2	5
60	Acute graft-vs-host disease Pathobiology and management. Experimental Hematology, 2001, 29, 259-277.	0.2	307
61	Advances in prevention and treatment of graft versus host disease. Expert Opinion on Therapeutic Patents, 2002, 12, 1385-1393.	2.4	0
62	Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 243-263.	1.8	17
63	Role of Dendritic Cells in Graft-Versus-Host Disease. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 601-616.	1.8	14
64	Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 2989-2994.	3.3	116
65	Role of the Passive Apoptotic Pathway in Graft-Versus-Host Disease. Journal of Immunology, 2002, 169, 1626-1633.	0.4	17
67	TNF- $\alpha$ targeted therapeutic approaches in patients with hematologic malignancies. Expert Review of Anticancer Therapy, 2002, 2, 277-286.	1.1	32
68	Accelerated Onset and Increased Severity of Acute Graft-Versus-Host Disease Following Adoptive Transfer of DR6-Deficient T Cells. Journal of Immunology, 2002, 169, 3993-3998.	0.4	8
69	A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplantation, 2002, 29, 373-377.	1.3	91
70	A two-phase pathogenesis of graft-versus-host disease in mice. Bone Marrow Transplantation, 2002, 29, 151-158.	1.3	23
71	Transplant-related toxicity and mortality: an AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia. Bone Marrow Transplantation, 2002, 29, 93-100.	1.3	30
72	The Balance Between Donor T Cell Anergy and Suppression Versus Lethal Graft-Versus-Host Disease Is Determined by Host Conditioning. Journal of Immunology, 2002, 169, 5581-5589.	0.4	41
73	APCs in the Liver and Spleen Recruit Activated Allogeneic CD8+ T Cells to Elicit Hepatic Graft-Versus-Host Disease. Journal of Immunology, 2002, 169, 7111-7118.	0.4	134

#	ARTICLE	IF	CITATIONS
74	Commentary on "Summary of Symposium: The Future of Stem Cell Transplantation for Sickle Cell Disease", <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 515-517.	0.3	1
75	Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. <i>Blood</i> , 2002, 100, 442-450.	0.6	50
76	Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. <i>Blood</i> , 2002, 99, 3033-3040.	0.6	72
77	Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. <i>Blood</i> , 2002, 100, 3429-3431.	0.6	37
78	Donor Lymphocyte Infusions to Treat Hematologic Malignancies in Relapse after Allogeneic Blood or Marrow Transplantation. <i>Cancer Control</i> , 2002, 9, 123-137.	0.7	87
79	The choice of allogeneic or autologous hematopoietic transplantation for NHL. <i>Cytotherapy</i> , 2002, 4, 259-269.	0.3	2
80	Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: Consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 608-618.	2.0	27
81	Critical Factors in Optimizing Graft-Versus-Leukemia Effect for Relapsed Leukemias. <i>Journal of Clinical Oncology</i> , 2002, 20, 2756-2757.	0.8	4
82	Update on non-myeloablative stem cell transplantation for hematologic malignancies. <i>International Journal of Hematology</i> , 2002, 76, 176-183.	0.7	9
83	Cellular and cytokine effectors of acute graft versus host disease. <i>International Journal of Hematology</i> , 2002, 76, 195-198.	0.7	22
84	Critical review on non-myeloablative stem cell transplantation (NST). <i>Critical Reviews in Oncology/Hematology</i> , 2002, 44, 175-190.	2.0	11
85	Naïve to memory T-cell differentiation during homeostasis-driven proliferation. <i>Microbes and Infection</i> , 2002, 4, 555-558.	1.0	25
86	High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 267-271.	1.3	21
87	An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 441-446.	1.3	46
88	Acute graft-versus-host disease does not require alloantigen expression on host epithelium. <i>Nature Medicine</i> , 2002, 8, 575-581.	15.2	495
89	The Danger Model: A Renewed Sense of Self. <i>Science</i> , 2002, 296, 301-305.	6.0	3,706
90	The Pathophysiology of Acute Graft-versus-Host Disease. <i>International Journal of Hematology</i> , 2003, 78, 181-187.	0.7	185
91	Graft-versus-Host Disease, the Graft-versus-Leukemia Effect, and Mixed Chimerism following Nonmyeloablative Stem Cell Transplantation. <i>International Journal of Hematology</i> , 2003, 78, 195-207.	0.7	14

#	ARTICLE	IF	CITATIONS
92	CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells. <i>Experimental Hematology</i> , 2003, 31, 81-88.	0.2	12
93	Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: Myeloablation with reduced toxicity. <i>Experimental Hematology</i> , 2003, 31, 428-434.	0.2	24
94	Role of CXCR3-induced donor T-cell migration in acute GVHD. <i>Experimental Hematology</i> , 2003, 31, 897-902.	0.2	152
95	Pathophysiology of acute graft-versus-host disease. <i>Hematological Oncology</i> , 2003, 21, 149-161.	0.8	145
96	Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. <i>International Journal of Cancer</i> , 2003, 105, 444-453.	2.3	44
97	Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 139-163.	2.0	23
98	The role of interferon-gamma, nitric oxide and lipopolysaccharide in intestinal graft-versus-host disease developing in F1-hybrid mice. <i>Immunology</i> , 2003, 109, 440-449.	2.0	33
99	Analysis of risk factors for acute cutaneous graft-versus-host disease after allogeneic stem cell transplantation. <i>British Journal of Dermatology</i> , 2003, 148, 1129-1134.	1.4	25
100	Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 32, 477-483.	1.3	6
101	Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. <i>Leukemia</i> , 2003, 17, 1150-1156.	3.3	145
102	Immunobiology of acute graft-versus-host disease. <i>Blood Reviews</i> , 2003, 17, 187-194.	2.8	234
103	Interleukin-11-induced heat shock protein 25 confers intestinal epithelial-specific cytoprotection from oxidant stress. <i>Gastroenterology</i> , 2003, 124, 1358-1368.	0.6	88
104	Intestinal Graft-Versus-Host Disease. <i>Drugs</i> , 2003, 63, 1-15.	4.9	38
105	Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 592-603.	2.0	19
106	Effects of Total Body Irradiation and Cyclosporin A on the Lethality of Toxic Shock Syndrome Toxinâ€™1 in a Rabbit Model of Toxic Shock Syndrome. <i>Journal of Infectious Diseases</i> , 2003, 188, 1142-1145.	1.9	11
107	Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. <i>Blood</i> , 2003, 102, 756-762.	0.6	531
108	Durable Remissions of Myelodysplastic Syndrome and Acute Myeloid Leukemia After Reduced-Intensity Allografting. <i>Journal of Clinical Oncology</i> , 2003, 21, 3060-3065.	0.8	60
109	Update on nonmyeloablative stem cell transplantation for hematologic malignancies. <i>Current Opinion in Organ Transplantation</i> , 2003, 8, 118-124.	0.8	1

#	ARTICLE	IF	CITATIONS
110	Infections in Patients with Hematological Cancer: Recent Developments. Hematology American Society of Hematology Education Program, 2003, 2003, 438-472.	0.9	93
111	Donor pretreatment with progenipoiectin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood, 2003, 101, 2033-2042.	0.6	64
112	Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood, 2003, 101, 2440-2445.	0.6	127
113	Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood, 2003, 101, 2877-2885.	0.6	65
114	Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood, 2003, 102, 763-771.	0.6	74
115	GITR Activation Induces an Opposite Effect on Alloreactive CD4+ and CD8+ T Cells in Graft-Versus-Host Disease. Journal of Experimental Medicine, 2004, 200, 149-157.	4.2	95
116	Pentostatin - pharmacology, immunology, and clinical effects in graft-versus-host disease. Expert Opinion on Pharmacotherapy, 2004, 5, 2605-2613.	0.9	8
117	Differential Roles for CCR5 Expression on Donor T Cells during Graft-versus-Host Disease Based on Pretransplant Conditioning. Journal of Immunology, 2004, 173, 845-854.	0.4	124
118	Clinical Implications of Minimal Residual Disease Monitoring for Stem Cell Transplantation after Reduced Intensity and Nonmyeloablative Conditioning. Acta Haematologica, 2004, 112, 93-104.	0.7	13
119	Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3921-3926.	3.3	278
120	Unexpected role of TNF- $\alpha$ in graft versus host reaction (GVHR): donor-derived TNF- $\alpha$ suppresses GVHR via inhibition of IFN- $\gamma$ -dependent donor type-1 immunity. International Immunology, 2004, 16, 811-817.	1.8	8
121	Association of Helicobacter pylori with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome after bone marrow transplantation. Clinical Transplantation, 2004, 18, 547-551.	0.8	13
122	Expression of TNF $\alpha$ by CD3+ and F4/80+ cells following irradiation preconditioning and allogeneic spleen cell transplantation. Bone Marrow Transplantation, 2004, 33, 359-365.	1.3	8
123	Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplantation, 2004, 33, 1143-1150.	1.3	87
124	Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease?. Bone Marrow Transplantation, 2004, 34, 753-765.	1.3	94
125	Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial. Bone Marrow Transplantation, 2004, 34, 577-580.	1.3	7
126	Reduced-intensity conditioning using TBI (8% Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplantation, 2004, 34, 1083-1088.	1.3	44
127	Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia, 2004, 18, 1789-1797.	3.3	107



#	ARTICLE	IF	CITATIONS
128	Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells. <i>Seminars in Oncology</i> , 2004, 31, 56-67.	0.8	14
129	Complete allogeneic hematopoietic chimerism achieved by in utero hematopoietic cell transplantation and cotransplantation of LLME-treated, MHC-sensitized donor lymphocytes. <i>Experimental Hematology</i> , 2004, 32, 290-299.	0.2	36
130	Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning. <i>Experimental Hematology</i> , 2004, 32, 1110-1117.	0.2	13
131	Acute graft-versus-host disease: Pathophysiology, clinical manifestations, and management. <i>Cancer</i> , 2004, 101, 1936-1946.	2.0	195
132	Advances in the genomics of allogeneic haemopoietic stem cell transplantation. <i>Drug Development Research</i> , 2004, 62, 273-292.	1.4	9
133	Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. <i>Blood</i> , 2004, 103, 4365-4367.	0.6	163
134	Recent Advances in the Treatment of Graft-Versus-Host Disease. <i>Clinical Medicine and Research</i> , 2004, 2, 243-252.	0.4	36
135	Enhancement of Allogeneic Hematopoietic Stem Cell Engraftment and Prevention of GvHD by Intra-Bone Marrow Bone Marrow Transplantation Plus Donor Lymphocyte Infusion. <i>Stem Cells</i> , 2004, 22, 125-134.	1.4	45
136	Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor $\pm$ with severe gut graft-versus-host disease. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 237-245.	2.4	44
137	Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 178-185.	2.0	192
138	Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 310-319.	2.0	39
139	Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 373-385.	2.0	26
140	Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 448-460.	2.0	8
141	Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 461-472.	2.0	34
142	Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 655-668.	2.0	71
144	An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. <i>Experimental Hematology</i> , 2004, 32, 318-324.	0.2	60
145	Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. <i>Blood</i> , 2004, 103, 50-57.	0.6	107
146	Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. <i>Blood</i> , 2004, 103, 3573-3581.	0.6	133

#	ARTICLE	IF	CITATIONS
147	Donor-derived TNF- $\alpha$ regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. <i>Blood</i> , 2004, 104, 586-593.	0.6	85
148	Chronic graft-versus-host disease after reduced-intensity stem cell transplantation versus conventional hematopoietic stem cell transplantation. <i>Hematology</i> , 2005, 10, 1-10.	0.7	10
149	Alpha phenyl-tert-butyl nitron (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration. <i>Blood</i> , 2005, 105, 428-431.	0.6	8
150	Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. <i>Blood</i> , 2005, 105, 894-901.	0.6	75
151	Donor CD8+ T cells facilitate induction of chimerism and tolerance without GVHD in autoimmune NOD mice conditioned with anti-CD3 mAb. <i>Blood</i> , 2005, 105, 2180-2188.	0.6	43
152	Critical role of host $\beta$ 1 T cells in experimental acute graft-versus-host disease. <i>Blood</i> , 2005, 106, 749-755.	0.6	67
153	Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. <i>Blood</i> , 2005, 106, 3293-3299.	0.6	110
154	TGF- $\beta$ 2 in allogeneic stem cell transplantation: friend or foe?. <i>Blood</i> , 2005, 106, 2206-2214.	0.6	136
155	Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. <i>Blood</i> , 2005, 106, 3285-3292.	0.6	44
156	CCR2 is required for CD8-induced graft-versus-host disease. <i>Blood</i> , 2005, 106, 3322-3330.	0.6	90
157	Variable Incidence of Cyclosporine and FK-506 Neurotoxicity in Hematopoietic Malignancies and Marrow Conditions After Allogeneic Bone Marrow Transplantation. <i>Neurocritical Care</i> , 2005, 3, 033-045.	1.2	34
158	Rare Incorporation of Bone Marrow-Derived Cells Into Kidney After Folic Acid-Induced Injury. <i>Stem Cells</i> , 2005, 23, 44-54.	1.4	56
159	Acute lung injury after allogeneic stem cell transplantation: From the clinic, to the bench and back again. <i>Pediatric Transplantation</i> , 2005, 9, 25-36.	0.5	29
160	The Pathophysiology of Acute Graft-Versus-Host Disease. <i>Scandinavian Journal of Immunology</i> , 2005, 61, 398-409.	1.3	43
161	Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2005, 129, 381-391.	1.2	41
162	Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. <i>British Journal of Haematology</i> , 2005, 130, 394-403.	1.2	110
163	Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. <i>British Journal of Haematology</i> , 2005, 130, 575-587.	1.2	38
164	Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. <i>Bone Marrow Transplantation</i> , 2005, 36, 683-689.	1.3	45

#	ARTICLE	IF	CITATIONS
165	Reduced p38 mitogen-activated protein kinase in donor grafts accelerates acute intestinal graft-versus-host disease in mice. <i>European Journal of Immunology</i> , 2005, 35, 2210-2221.	1.6	3
166	Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration. <i>Cancer</i> , 2005, 103, 191-199.	2.0	145
167	Evaluation of potential risk factors for early infectious complications after autologous peripheral blood stem cell transplantation in patients with lymphoproliferative diseases. <i>Annals of Hematology</i> , 2005, 84, 532-537.	0.8	14
168	Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: a new therapeutic option or just a clinical experiment?. <i>World Journal of Urology</i> , 2005, 23, 213-220.	1.2	3
169	Lacrimal Gland Involvement in Graft-Versus-Host Disease: A Murine Model. , 2005, 46, 2692.		31
170	Absence of host tumor necrosis factor receptor 1 attenuates manifestations of idiopathic pneumonia syndrome. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2005, 288, L942-L949.	1.3	20
171	Heat Shock Protein 10 Inhibits Lipopolysaccharide-induced Inflammatory Mediator Production. <i>Journal of Biological Chemistry</i> , 2005, 280, 4037-4047.	1.6	158
172	Reduced-Intensity Conditioning Regimens for Hematologic Malignancies: What Have We Learned over the Last 10 Years?. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 384-389.	0.9	30
173	CD34+ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2005, 46, 177-183.	0.6	24
174	Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2005, 46, 1251-1260.	0.6	46
175	Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. <i>Trends in Immunology</i> , 2005, 26, 111-117.	2.9	410
176	Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 101-107.	2.0	39
177	Sequential Expression of Adhesion and Costimulatory Molecules in Graft-versus-Host Disease Target Organs after Murine Bone Marrow Transplantation across Minor Histocompatibility Antigen Barriers. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 371-382.	2.0	34
178	Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future Challenges. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 403-422.	2.0	38
179	Pilot Trial on the Use of Etanercept and Methylprednisolone as Primary Treatment for Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 680-687.	2.0	89
180	Pathophysiology of Graft-Versus-Host Disease. <i>Seminars in Hematology</i> , 2006, 43, 3-10.	1.8	358
182	Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 668-681.	4.3	318
183	Human 6-Sulfo LacNAc-Expressing Dendritic Cells Are Principal Producers of Early Interleukin-12 and Are Controlled by Erythrocytes. <i>Immunity</i> , 2006, 24, 767-777.	6.6	178

#	ARTICLE	IF	CITATIONS
184	Absence of $\beta 27$ integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. <i>Blood</i> , 2006, 107, 1703-1711.	0.6	106
185	NF- $\kappa$ B as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. <i>Blood</i> , 2006, 107, 827-834.	0.6	109
186	G-CSF-treated granulocytes inhibit acute graft-versus-host disease. <i>Blood</i> , 2006, 107, 2192-2199.	0.6	33
187	Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. <i>Blood</i> , 2006, 108, 2485-2492.	0.6	121
188	Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). <i>Blood</i> , 2006, 108, 3216-3222.	0.6	147
189	No Evidence of Association between NOD2/CARD15 Gene Polymorphism and Atherosclerotic Events after Renal Transplantation. <i>Transplantation</i> , 2006, 81, 1212-1215.	0.5	6
190	Intrinsic properties of human and murine memory B cells. <i>Immunological Reviews</i> , 2006, 211, 280-294.	2.8	47
191	Adoptive immunotherapy for cancer: building on success. <i>Nature Reviews Immunology</i> , 2006, 6, 383-393.	10.6	801
192	Differential effect of conditioning regimens on cytokine responses during allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 37, 635-640.	1.3	20
193	Poor oral nutrition after allogeneic stem cell transplantation correlates significantly with severe graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2006, 38, 629-633.	1.3	87
194	Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. <i>Leukemia</i> , 2006, 20, 1661-1672.	3.3	112
195	Shared biology of GVHD and GVT effects: Potential methods of separation. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 225-244.	2.0	67
196	Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade. <i>Annals of Hematology</i> , 2006, 86, 127-132.	0.8	10
197	Key factors in experimental mouse hematopoietic stem cell transplantation. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2006, 54, 253-269.	1.0	8
198	Improved survival following induction of GVHD following lipopolysaccharide immunization. <i>Experimental Hematology</i> , 2006, 34, 549-553.	0.2	6
199	TRAIL-induced cell death cooperates with IFN- $\gamma$ activation in the graft-versus-tumor effect against colon tumors. <i>International Journal of Cancer</i> , 2006, 118, 2237-2246.	2.3	13
200	Analysis of serum granulysin in patients with hematopoietic stem-cell transplantation: Its usefulness as a marker of graft-versus-host reaction. <i>American Journal of Hematology</i> , 2006, 81, 340-348.	2.0	26
201	Palifermin: a keratinocyte growth factor that reduces oral mucositis after stem cell transplant for haematological malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2287-2299.	0.9	19

#	ARTICLE	IF	CITATIONS
202	An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. <i>Journal of Experimental Medicine</i> , 2006, 203, 2021-2031.	4.2	170
203	Severely Impaired Clonal Deletion of CD4+ T Cells in Low-Dose Irradiated Mice: Role of T Cell Antigen Receptor and IL-7 Receptor Signals. <i>Journal of Immunology</i> , 2006, 177, 8320-8330.	0.4	19
204	Host-Derived Langerhans Cells Persist after MHC-Matched Allografting Independent of Donor T Cells and Critically Influence the Alloresponses Mediated by Donor Lymphocyte Infusions. <i>Journal of Immunology</i> , 2006, 177, 4414-4425.	0.4	36
205	Donor CD8+ T Cells Mediate Graft-versus-Leukemia Activity without Clinical Signs of Graft-versus-Host Disease in Recipients Conditioned with Anti-CD3 Monoclonal Antibody. <i>Journal of Immunology</i> , 2007, 178, 838-850.	0.4	30
206	IFN- $\gamma$ and Fas Ligand Are Required for Graft-versus-Tumor Activity against Renal Cell Carcinoma in the Absence of Lethal Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2007, 179, 1669-1680.	0.4	19
207	Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G1114-G1123.	1.6	8
208	Radiation protocols determine acute graft-versus-host disease incidence after allogeneic bone marrow transplantation in murine models. <i>International Journal of Radiation Biology</i> , 2007, 83, 625-636.	1.0	8
209	Toll-like Receptors in Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 5280-5289.	3.2	114
210	Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. <i>Blood</i> , 2007, 109, 3115-3123.	0.6	139
211	Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease. <i>Blood</i> , 2007, 110, 776-782.	0.6	34
212	The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. <i>Blood</i> , 2007, 110, 9-17.	0.6	150
213	IFN- $\gamma$ differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. <i>Blood</i> , 2007, 110, 1064-1072.	0.6	159
214	Reduced-Intensity Stem Cell Transplantation for Hematological Malignancies: Current Status and the Future. <i>Current Stem Cell Research and Therapy</i> , 2007, 2, 149-162.	0.6	7
215	New Directions in the Genomics of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 127-144.	2.0	40
216	The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 521-529.	2.0	13
217	Comparable Outcomes after Nonmyeloablative Hematopoietic Cell Transplantation with Unrelated and Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1499-1507.	2.0	39
218	DC homeostasis in hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2007, 9, 521-531.	0.3	8
219	Graft-Versus-Host Disease: Review and Nursing Implications. <i>Clinical Journal of Oncology Nursing</i> , 2007, 11, 325-328.	0.3	17

#	ARTICLE	IF	CITATIONS
220	The Effect of Palifermin on Chemotherapy and Radiation Therapy-Induced Mucositis: A Review of the Current Literature. <i>Supportive Cancer Therapy</i> , 2007, 4, 188-197.	0.3	24
221	Death Receptors and Apoptosis. <i>Dermatologic Clinics</i> , 2007, 25, 487-501.	1.0	28
222	Pathophysiology of acute graft-versus-host disease: recent advances. <i>Translational Research</i> , 2007, 150, 197-214.	2.2	110
223	Immunobiology of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Annual Review of Immunology</i> , 2007, 25, 139-170.	9.5	454
224	Novel strategies for the treatment and diagnosis of graft-versus-host-disease. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 91-97.	0.7	36
225	Cobalt protoporphyrine IX-mediated heme oxygenase-I induction alters the inflammatory cytokine response, but not antigen presentation after experimental allogeneic bone marrow transplantation. <i>International Journal of Molecular Medicine</i> , 0, , .	1.8	5
226	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. <i>Journal of Clinical Investigation</i> , 2007, 117, 2197-2204.	3.9	456
227	Graft-versus-host disease. <i>Nature Reviews Immunology</i> , 2007, 7, 340-352.	10.6	680
228	Infliximab for GVHD therapy in children. <i>Bone Marrow Transplantation</i> , 2007, 40, 473-480.	1.3	48
229	Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. <i>Leukemia</i> , 2007, 21, 1992-1999.	3.3	167
230	Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. <i>Leukemia</i> , 2007, 21, 2109-2116.	3.3	98
231	Advances in the understanding of acute graft-versus-host disease. <i>British Journal of Haematology</i> , 2007, 137, 3-19.	1.2	44
232	Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease. <i>Experimental Hematology</i> , 2007, 35, 155-163.	0.2	19
233	Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. <i>Experimental Hematology</i> , 2007, 35, 184-192.	0.2	63
234	Thymus repopulation after allogeneic reconstitution in hematological malignancies. <i>Experimental Hematology</i> , 2007, 35, 1891-1905.	0.2	9
235	Gut Toxicity During Hemopoietic Stem Cell Transplantation May Predict Acute Graft-Versus-Host Disease Severity in Patients. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2340-2345.	1.1	49
236	The absence of donor-derived IL-13 exacerbates the severity of acute graft-versus-host disease following allogeneic bone marrow transplantation. <i>Pediatric Blood and Cancer</i> , 2008, 50, 911-914.	0.8	6
237	IFN- $\gamma$ activation of mesenchymal stem cells for treatment and prevention of graft-versus-host disease. <i>European Journal of Immunology</i> , 2008, 38, 1745-1755.	1.6	528

#	ARTICLE	IF	CITATIONS
238	GVHD after chemotherapy conditioning in allogeneic transplanted mice. Bone Marrow Transplantation, 2008, 42, 807-818.	1.3	44
239	Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nature Biotechnology, 2008, 26, 453-461.	9.4	110
240	Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model. Gene Therapy, 2008, 15, 171-182.	2.3	79
241	Impact of cytokine gene polymorphisms on graft-vs-host disease. Tissue Antigens, 2008, 72, 507-516.	1.0	19
242	The potential role of lactoferrin and derivatives in the management of infectious and inflammatory complications of hematology patients receiving a hematopoietic stem cell transplantation. Transplant Infectious Disease, 2008, 10, 80-89.	0.7	14
243	Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant radiation conditioning and local cytokine dysregulation in promoting lung inflammation and fibrosis. International Journal of Experimental Pathology, 2008, 82, 101-113.	0.6	61
244	Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. Experimental Hematology, 2008, 36, 988-996.	0.2	56
245	Human Immunodeficiency Virus-Related Microbial Translocation and Progression of Hepatitis C. Gastroenterology, 2008, 135, 226-233.	0.6	251
246	GVHD pathophysiology: is acute different from chronic?. Best Practice and Research in Clinical Haematology, 2008, 21, 101-117.	0.7	71
247	Chronic GVHD as an autoimmune disease. Best Practice and Research in Clinical Haematology, 2008, 21, 281-289.	0.7	47
248	Mouse Models of Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 129-135.	2.0	98
249	Plasma Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 Postallogeneic Transplant Correlate with Graft-versus-Host Disease Severity and Overall Survival in Pediatric Patients. Biology of Blood and Marrow Transplantation, 2008, 14, 759-765.	2.0	36
250	Influence of Polymorphism within the Heme Oxygenase-I Promoter on Overall Survival and Transplantation-Related Mortality after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 1180-1189.	2.0	13
251	Role of dendritic cells and chemokines in acute graft-versus-host disease. Frontiers in Bioscience - Landmark, 2008, 13, 2065.	3.0	4
252	Posterior Reversible Encephalopathy Syndrome, Part 2: Controversies Surrounding Pathophysiology of Vasogenic Edema. American Journal of Neuroradiology, 2008, 29, 1043-1049.	1.2	914
253	The Host Environment Regulates the Function of CD8+ Graft-versus-Host-Reactive Effector Cells. Journal of Immunology, 2008, 181, 6820-6828.	0.4	29
254	Breaking of CD8+ T Cell Tolerance through In Vivo Ligation of CD40 Results in Inhibition of Chronic Graft-versus-Host Disease and Complete Donor Cell Engraftment. Journal of Immunology, 2008, 181, 7380-7389.	0.4	15
255	Critical Role of TLR9 in Acute Graft-versus-Host Disease. Journal of Immunology, 2008, 181, 6132-6139.	0.4	70

#	ARTICLE	IF	CITATIONS
256	Organ-derived dendritic cells have differential effects on alloreactive T cells. <i>Blood</i> , 2008, 111, 2929-2940.	0.6	28
257	Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. <i>Blood</i> , 2008, 112, 1539-1542.	0.6	128
258	Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2008, 111, 2462-2469.	0.6	42
259	Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. <i>Blood</i> , 2008, 112, 1515-1521.	0.6	198
260	Protection from graft-versus-host disease with a novel B7 binding site-specific mouse anti-mouse CD28 monoclonal antibody. <i>Blood</i> , 2008, 112, 4328-4336.	0.6	27
261	Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem-Cell Transplant Determines the Kinetics of Acute Graft-Versus-Host Disease. <i>Transplantation</i> , 2008, 86, 968-976.	0.5	29
262	Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 2562-73.	3.9	243
263	Role of Type II NKT Cells in the Suppression of Graft-versus-Host Disease. <i>Critical Reviews in Immunology</i> , 2008, 28, 249-267.	1.0	7
264	Pathobiology of graft-versus-host disease. , 0, , 313-330.		0
265	Radiotherapeutic Principles of Hematopoietic Cell Transplantation. , 0, , 333-350.		0
266	Î³Î´ T Lymphocyte Homeostasis Is Negatively Regulated by Î²2-Microglobulin. <i>Journal of Immunology</i> , 2009, 182, 1892-1900.	0.4	11
267	Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. <i>Journal of Experimental Medicine</i> , 2009, 206, 387-398.	4.2	68
268	Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. <i>Journal of Experimental Medicine</i> , 2009, 206, 371-385.	4.2	222
269	Tissue-Specific Homing and Expansion of Donor NK Cells in Allogeneic Bone Marrow Transplantation. <i>Journal of Immunology</i> , 2009, 183, 3219-3228.	0.4	52
270	Combination approaches to immunotherapy: the radiotherapy example. <i>Immunotherapy</i> , 2009, 1, 1025-1037.	1.0	29
271	Cryptococcosis in Solid-Organ, Hematopoietic Stem Cell, and Tissue Transplant Recipients: Evidence-Based Evolving Trends. <i>Clinical Infectious Diseases</i> , 2009, 48, 1566-1576.	2.9	100
272	Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 484-498.	3.3	19
273	Adult thymus transplantation with allogeneic intra-bone marrow-bone marrow transplantation from same donor induces high thymopoiesis, mild graft-versus-host reaction and strong graft-versus-tumour effects. <i>Immunology</i> , 2009, 126, 552-564.	2.0	16



#	ARTICLE	IF	CITATIONS
274	Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. <i>Clinical and Experimental Immunology</i> , 2009, 157, 104-118.	1.1	334
275	Gut protection by palifermin during autologous haematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2009, 43, 807-811.	1.3	20
276	Cutaneous lymphocyte antigen-positive T cells may predict the development of acute GVHD: alterations and differences of CLA+ T- and NK-cell fractions. <i>Bone Marrow Transplantation</i> , 2009, 43, 863-873.	1.3	14
277	Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2009, 44, 413-425.	1.3	63
278	Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation. <i>Nature Medicine</i> , 2009, 15, 436-441.	15.2	64
279	Nutrition, anthropometry, gastrointestinal dysfunction, and circulating levels of tumour necrosis factor alpha receptor 1 and interleukin-1 receptor antagonist in children during stem cell transplantation. <i>Pediatric Transplantation</i> , 2009, 13, 182-187.	0.5	9
280	The Role of Innate Immunity in Graft-Versus-Host Disease and Complications following Allogeneic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 59-61.	2.0	8
281	Regulatory Mechanisms in Graft-versus-Host Responses. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 2-6.	2.0	21
282	Inflammation and Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 139-141.	2.0	29
283	Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 306-314.	2.0	19
284	Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with Very Low Incidence of GVHD and Nonrelapse Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 919-929.	2.0	40
285	The Pathophysiology of Graft-Versus-Host Disease. , 0, , 208-221.		2
286	Mouse models of graft-versus-host disease. <i>Stembook</i> , 2009, , .	0.3	15
287	Graft-versus-host disease. <i>Lancet, The</i> , 2009, 373, 1550-1561.	6.3	2,093
288	Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. <i>Blood</i> , 2009, 113, 2088-2095.	0.6	92
289	Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. <i>Blood</i> , 2009, 113, 2352-2362.	0.6	70
290	Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after $\beta$ -galactosylceramide administration. <i>Blood</i> , 2009, 113, 5999-6010.	0.6	28
291	Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. <i>Blood</i> , 2009, 114, 3693-3706.	0.6	28

#	ARTICLE	IF	CITATIONS
292	Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. <i>Blood</i> , 2009, 114, 891-900.	0.6	257
293	Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease. <i>Blood</i> , 2009, 114, 4575-4582.	0.6	32
294	The Pathophysiology of Acute Graft versus Host Disease. , 0, , 8-16.		0
295	The Protective Role of Host Toll-Like Receptor-4 in Acute Graft-Versus-Host Disease. <i>Transplantation</i> , 2010, 90, 1063-1070.	0.5	34
296	Soluble lymphotoxin is an important effector molecule in GVHD and GVL. <i>Blood</i> , 2010, 115, 122-132.	0.6	49
297	Gas6 deficiency in recipient mice of allogeneic transplantation alleviates hepatic graft-versus-host disease. <i>Blood</i> , 2010, 115, 3390-3397.	0.6	9
298	Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses. <i>Blood</i> , 2010, 115, 5249-5258.	0.6	47
299	Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. <i>Blood</i> , 2010, 116, 819-828.	0.6	139
300	Chemotherapy Foundation Symposium XXVIII Innovative Cancer Therapy For Tomorrow Abstracts 2010. Current Treatment Options in Oncology, 2010, 11, 1-104.	1.3	9
301	Leishmaniasis, contact hypersensitivity and graft-versus-host disease: understanding the role of dendritic cell subsets in balancing skin immunity and tolerance. <i>Experimental Dermatology</i> , 2010, 19, 760-771.	1.4	11
302	Influence of oral beclomethasone dipropionate on early non-infectious pulmonary outcomes after allogeneic hematopoietic cell transplantation: results from two randomized trials. <i>Bone Marrow Transplantation</i> , 2010, 45, 317-324.	1.3	6
303	Early thrombin generation and impaired fibrinolysis after SCT associate with acute GVHD. <i>Bone Marrow Transplantation</i> , 2010, 45, 730-737.	1.3	18
304	New perspectives on the biology of acute GVHD. <i>Bone Marrow Transplantation</i> , 2010, 45, 1-11.	1.3	158
305	<i>Clostridium difficile</i> -associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. <i>Clinical Transplantation</i> , 2010, 24, 192-198.	0.8	72
306	Hematopoietic stem cell transplantation for the management of follicular lymphoma. <i>Stem Cells and Cloning: Advances and Applications</i> , 2010, 3, 69.	2.3	0
307	Roles of Host Nonhematopoietic Cells in Autoimmunity and Donor Cell Engraftment in Graft-versus-host Disease. <i>Immune Network</i> , 2010, 10, 46.	1.6	3
308	A Role for IL-1 Receptor-Associated Kinase-M in Prostaglandin E2-Induced Immunosuppression Post-Bone Marrow Transplantation. <i>Journal of Immunology</i> , 2010, 184, 6299-6308.	0.4	47
309	Therapeutic Glucocorticoid-Induced TNF Receptor-Mediated Amplification of CD4+T Cell Responses Enhances Antiparasitic Immunity. <i>Journal of Immunology</i> , 2010, 184, 2583-2592.	0.4	17

#	ARTICLE	IF	CITATIONS
310	The CCL3/Macrophage Inflammatory Protein-1 $\beta$ Binding Protein Evasin-1 Protects from Graft-versus-Host Disease but Does Not Modify Graft-versus-Leukemia in Mice. <i>Journal of Immunology</i> , 2010, 184, 2646-2654.	0.4	51
311	Expansion and Activation Kinetics of Immune Cells during Early Phase of GVHD in Mouse Model Based on Chemotherapy Conditioning. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-13.	3.3	16
312	Inhibition of Neovascularization to Simultaneously Ameliorate Graft-vs-Host Disease and Decrease Tumor Growth. <i>Journal of the National Cancer Institute</i> , 2010, 102, 894-908.	3.0	53
313	Association between chronic liver and colon inflammation during the development of murine syngeneic graft-versus-host disease. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G602-G613.	1.6	6
314	The Chemokine System: A Possible Therapeutic Target in Acute Graft Versus Host Disease. <i>Current Topics in Microbiology and Immunology</i> , 2010, 341, 97-120.	0.7	19
315	Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. <i>Bone Marrow Transplantation</i> , 2010, 45, 1442-1448.	1.3	16
316	Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. <i>Immunotherapy</i> , 2010, 2, 399-418.	1.0	36
317	Reduced intensity conditioning for hematopoietic stem cell transplantation: has it achieved all it set out to?. <i>Cytotherapy</i> , 2010, 12, 440-454.	0.3	6
318	Early and late-onset acute GvHD following hematopoietic cell transplantation: CT features of gastrointestinal involvement with clinical and pathological correlation. <i>European Journal of Radiology</i> , 2010, 73, 594-600.	1.2	39
319	Association of HMGB1 Polymorphisms with Outcome after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 239-252.	2.0	49
320	Tumor Necrosis Factor $\beta$ Gene Polymorphisms Are Associated with Severity of Acute Graft-Versus-Host Disease Following Matched Unrelated Donor Bone Marrow Transplantation in Children: A Pediatric Blood and Marrow Transplant Consortium Study. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 927-936.e1.	2.0	21
321	The Chemokine System in Experimental and Clinical Hematology. <i>Current Topics in Microbiology and Immunology</i> , 2010, , .	0.7	6
322	Human umbilical cord blood-derived stromal cells prevent graft-versus-host disease in mice following haplo-identical stem cell transplantation. <i>Cytotherapy</i> , 2011, 13, 83-91.	0.3	16
323	Effect of Solar Particle Event Radiation on Gastrointestinal Tract Bacterial Translocation and Immune Activation. <i>Radiation Research</i> , 2011, 175, 485-492.	0.7	16
324	Mouse models of graft-versus-host disease: advances and limitations. <i>DMM Disease Models and Mechanisms</i> , 2011, 4, 318-333.	1.2	238
325	Translational Research Efforts in Biomarkers and Biology of Early Transplant-Related Complications. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S101-S108.	2.0	5
326	Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1862-1868.	2.0	109
327	Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1747-1753.	2.0	8

#	ARTICLE	IF	CITATIONS
328	Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome. <i>Seminars in Immunology</i> , 2011, 23, 50-57.	2.7	13
329	Role of gut microbiota in graft-versus-host disease. <i>Leukemia and Lymphoma</i> , 2011, 52, 1844-1856.	0.6	47
330	HDAC Inhibition and Graft Versus Host Disease. <i>Molecular Medicine</i> , 2011, 17, 404-416.	1.9	71
331	Blockade of Vascular Endothelial Growth Factor (VEGF) Aggravates the Severity of Acute Graft-versus-host Disease (GVHD) after Experimental Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). <i>Immune Network</i> , 2011, 11, 368.	1.6	7
332	Type I-HFNs control GVHD and GVL responses after transplantation. <i>Blood</i> , 2011, 118, 3399-3409.	0.6	64
333	Human peripheral blood CD4 T cell-engrafted non-obese diabetic- <i>scid</i> IL2r <sup>Δ</sup> null H2-Ab1 tm1Gru <sup>Δ</sup> Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease. <i>Clinical and Experimental Immunology</i> , 2011, 166, 269-280.	1.1	88
334	Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia. <i>Bone Marrow Transplantation</i> , 2011, 46, 34-43.	1.3	20
335	Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract. <i>Experimental Hematology</i> , 2011, 39, 238-249.e1.	0.2	30
336	The influence of pretransplantation conditioning on graft-vs.-leukemia effect in mice. <i>Experimental Hematology</i> , 2011, 39, 1018-1029.	0.2	7
337	Early expression of plasma CCL8 closely correlates with survival rate of acute graft-vs.-host disease in mice. <i>Experimental Hematology</i> , 2011, 39, 1101-1112.	0.2	19
338	Implications of TNF- $\alpha$ in the pathogenesis and management of GVHD. <i>International Journal of Hematology</i> , 2011, 93, 571-577.	0.7	70
339	Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation. <i>International Journal of Hematology</i> , 2011, 93, 509-516.	0.7	8
340	Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease. <i>Pediatric Blood and Cancer</i> , 2011, 56, 45-49.	0.8	15
341	Galectin-9 ameliorates acute GVH disease through the induction of T cell apoptosis. <i>European Journal of Immunology</i> , 2011, 41, 67-75.	1.6	42
342	Regulatory T cells and IL-17-producing cells in graft-versus-host disease. <i>Immunotherapy</i> , 2011, 3, 833-852.	1.0	31
343	The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 637-646.	1.5	25
344	An Official American Thoracic Society Research Statement: Noninfectious Lung Injury after Hematopoietic Stem Cell Transplantation: Idiopathic Pneumonia Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1262-1279.	2.5	271
345	Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. <i>Bone Marrow Transplantation</i> , 2011, 46, 580-585.	1.3	22

#	ARTICLE	IF	CITATIONS
346	Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. <i>Journal of Experimental Medicine</i> , 2011, 208, 1069-1082.	4.2	145
347	The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells. <i>Journal of Experimental Medicine</i> , 2011, 208, 285-294.	4.2	129
348	PI3K $\beta$ controls leukocyte recruitment, tissue injury, and lethality in a model of graft-versus-host disease in mice. <i>Journal of Leukocyte Biology</i> , 2011, 89, 955-964.	1.5	23
349	Manipulating the Bioenergetics of Alloreactive T Cells Causes Their Selective Apoptosis and Arrests Graft-Versus-Host Disease. <i>Science Translational Medicine</i> , 2011, 3, 67ra8.	5.8	153
350	Instability of Foxp3 Expression Limits the Ability of Induced Regulatory T Cells to Mitigate Graft versus Host Disease. <i>Clinical Cancer Research</i> , 2011, 17, 3969-3983.	3.2	81
351	Graft-versus-Host Disease Is Independent of Innate Signaling Pathways Triggered by Pathogens in Host Hematopoietic Cells. <i>Journal of Immunology</i> , 2011, 186, 230-241.	0.4	62
352	Accumulation of CD4+T cells in the colon of CsA-treated mice following myeloablative conditioning and bone marrow transplantation. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, G843-G852.	1.6	3
353	Relationship between TNFA, TNFB and TNFR1I gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in a Chinese population. <i>Bone Marrow Transplantation</i> , 2011, 46, 400-407.	1.3	17
354	Ocular graft-versus-host disease. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 540-547.	1.1	104
355	Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. <i>Journal of Experimental Medicine</i> , 2012, 209, 903-911.	4.2	552
356	Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 564-569.	3.3	125
357	Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. <i>Nature Medicine</i> , 2012, 18, 135-142.	15.2	206
358	Novel Role for Surfactant Protein A in Gastrointestinal Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2012, 188, 4897-4905.	0.4	9
359	Th17 Mediated Alloreactivity Is Facilitated by the Pre-Transplant Microbial Burden of the Recipient. <i>Bone Marrow Research</i> , 2012, 2012, 1-5.	1.7	24
360	Role of Cytokines in the Pathophysiology of Acute Graft-Versus-Host Disease (GVHD) – Are Serum/Plasma Cytokines Potential Biomarkers for Diagnosis of Acute GVHD Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)? <i>Current Stem Cell Research and Therapy</i> , 2012, 7, 229-239.	0.6	37
361	Better Outcome of Patients Undergoing Enteral Tube Feeding After Myeloablative Conditioning for Allogeneic Stem Cell Transplantation. <i>Transplantation</i> , 2012, 94, 287-294.	0.5	90
362	Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2012, 97, 867-873.	1.7	34
363	Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. <i>Blood</i> , 2012, 119, 3844-3853.	0.6	86

#	ARTICLE	IF	CITATIONS
364	Nonalloreactive T Cells Prevent Donor Lymphocyte Infusion-Induced Graft-versus-Host Disease by Controlling Microbial Stimuli. <i>Journal of Immunology</i> , 2012, 189, 5572-5581.	0.4	9
365	Is Graft-versus-Leukemia More Effective Using Reduced-Intensity Conditioning Compared with Myeloablative Conditioning?. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1615-1617.	2.0	2
366	TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1525-1532.	2.0	50
367	Phase I Study of the Tolerability and Pharmacokinetics of Palifermin in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1309-1314.	2.0	21
368	Graft-versus-host disease. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 515.e1-515.e18.	0.6	52
369	Host CD25+CD4+Foxp3+ Regulatory T Cells Primed by anti-CD137 mAbs Inhibit Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 44-54.	2.0	18
370	The IL-17 Differentiation Pathway and Its Role in Transplant Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S56-S61.	2.0	74
371	GVHD Prevention: An Ounce Is Better Than a Pound. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S17-S26.	2.0	10
372	Comparison of three humanized mouse models for adoptive T cell transfer. <i>Journal of Gene Medicine</i> , 2012, 14, 540-548.	1.4	4
373	Myeloablative Radioimmunotherapy in Conditioning of Acute Leukemia, MDS, and Multiple Myeloma Prior to Hematological Stem Cell Transplantation. <i>Medical Radiology</i> , 2012, , 669-683.	0.0	0
374	Rosiglitazone prevents graft-versus-host disease (GVHD). <i>Transplant Immunology</i> , 2012, 27, 128-137.	0.6	7
376	Radiation-Free Allogeneic Conditioning with Fludarabine, Carmustine, and Thiotepa for Acute Lymphoblastic Leukemia and Other Hematologic Malignancies Necessitating Enhanced Central Nervous System Activity. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1430-1437.	2.0	15
377	Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e35222.	1.1	5
378	The Role of Chemokines in Mediating Graft Versus Host Disease: Opportunities for Novel Therapeutics. <i>Frontiers in Pharmacology</i> , 2012, 3, 23.	1.6	30
379	Emerging concepts in haematopoietic cell transplantation. <i>Nature Reviews Immunology</i> , 2012, 12, 403-416.	10.6	105
380	The interferon-dependent orchestration of innate and adaptive immunity after transplantation. <i>Blood</i> , 2012, 119, 5351-5358.	0.6	40
381	Immune insufficiency during GVHD is due to defective antigen presentation within dendritic cell subsets. <i>Blood</i> , 2012, 119, 5918-5930.	0.6	32
382	Identification and expansion of highly suppressive CD8+FoxP3+ regulatory T cells after experimental allogeneic bone marrow transplantation. <i>Blood</i> , 2012, 119, 5898-5908.	0.6	114

#	ARTICLE	IF	CITATIONS
383	Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract. <i>British Journal of Haematology</i> , 2012, 157, 403-407.	1.2	18
384	Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target?. <i>Bone Marrow Transplantation</i> , 2013, 48, 284-293.	1.3	22
386	Hydrogen therapy may be an effective and specific novel treatment for Acute Graft-versus-Host disease ( ) Tj ETQc0 0 0 rgBT /Overlo	1.6	13
387	Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology - a systematic review. <i>BMC Veterinary Research</i> , 2013, 9, 123.	0.7	181
388	Treatment of Graft-versus-Host Disease with Naturally Occurring T Regulatory Cells. <i>BioDrugs</i> , 2013, 27, 605-614.	2.2	35
389	Diagnosis and evaluation of intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation following reduced-intensity and myeloablative conditioning regimens. <i>International Journal of Hematology</i> , 2013, 97, 421-426.	0.7	3
390	Prevention of Acute Graft-versus-Host Disease in a Xenogeneic SCID Mouse Model by the Humanized Anti-CD74 Antagonistic Antibody Milatuzumab. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 28-39.	2.0	15
391	Ocular Graft-versus-Host Disease: A Review. <i>Survey of Ophthalmology</i> , 2013, 58, 233-251.	1.7	182
392	Induced Regulatory T Cells Promote Tolerance When Stabilized by Rapamycin and IL-2 In Vivo. <i>Journal of Immunology</i> , 2013, 191, 5291-5303.	0.4	101
393	Acute graft-versus-host disease: Are we close to bringing the bench to the bedside?. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 285-292.	0.7	19
394	Advances in the treatment of acute graft-versus-host disease. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 966-975.	1.6	40
395	Severe Hyperglycemia Immediately After Allogeneic Hematopoietic Stem-Cell Transplantation is Predictive of Acute Graft-Versus-Host Disease. <i>Inflammation</i> , 2013, 36, 177-185.	1.7	32
396	Successful Treatment of Both Acute Leukemia and Active Crohn's Disease After Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning With Fludarabine and Busulfan: A Case Report. <i>Transplantation Proceedings</i> , 2013, 45, 2854-2857.	0.3	4
397	Migration and Activation of T Cells During Development of Graft-Versus-Host Disease in a Mouse Model. <i>Transplantation Proceedings</i> , 2013, 45, 713-718.	0.3	3
398	Tryptophan metabolite analog, N-(3,4-dimethoxycinnamonyl) anthranilic acid, ameliorates acute graft-versus-host disease through regulating T cell proliferation and polarization. <i>International Immunopharmacology</i> , 2013, 17, 601-607.	1.7	7
399	Glutamine protects mice from acute graft-versus-host disease (aGVHD). <i>Biochemical and Biophysical Research Communications</i> , 2013, 435, 94-99.	1.0	19
400	New ways to separate Graft-versus-Host Disease and Graft-versus-Tumour effects after allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2013, 160, 133-145.	1.2	21
401	Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 692-702.	2.0	61

#	ARTICLE	IF	CITATIONS
402	Human mesenchymal stem cells suppress donor CD4+ T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. <i>Clinical and Experimental Immunology</i> , 2013, 172, 333-348.	1.1	107
403	Impact of the conditioning regimen. , 2013, , 165-171.		0
404	Cytokines in graft-versus-host disease and graft-versus-leukemia. , 2013, , 357-391.		0
405	Chemokines and graft-versus-host disease. , 2013, , 393-424.		6
406	Mesenchymal stromal cell supported umbilical cord blood ex vivo expansion enhances regulatory T cells and reduces graft versus host disease. <i>Cytotherapy</i> , 2013, 15, 610-619.	0.3	22
407	Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice. <i>Immunogenetics</i> , 2013, 65, 597-607.	1.2	3
408	Microbial Translocation in the Pathogenesis of HIV Infection and AIDS. <i>Clinical Microbiology Reviews</i> , 2013, 26, 2-18.	5.7	404
409	Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission: single-centre results after TBI-based myeloablative and non-myeloablative conditioning. <i>Bone Marrow Transplantation</i> , 2013, 48, 1185-1191.	1.3	8
411	Efficacy of azithromycin in preventing lethal graft-versus-host disease. <i>Clinical and Experimental Immunology</i> , 2013, 171, 338-345.	1.1	15
412	Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 1371-1384.	1.6	51
413	IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect. <i>Leukemia</i> , 2013, 27, 1527-1537.	3.3	77
414	Concise Review: Acute Graft-Versus-Host Disease: Immunobiology, Prevention, and Treatment. <i>Stem Cells Translational Medicine</i> , 2013, 2, 25-32.	1.6	119
416	Promoting regulation via the inhibition of DNAM-1 after transplantation. <i>Blood</i> , 2013, 121, 3511-3520.	0.6	47
417	A critical role for the retinoic acid signaling pathway in the pathophysiology of gastrointestinal graft-versus-host disease. <i>Blood</i> , 2013, 121, 3970-3980.	0.6	27
418	Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. <i>Blood</i> , 2013, 122, 2125-2134.	0.6	47
419	Administration of Hydrogen-Rich Saline Protects Mice From Lethal Acute Graft-Versus-Host Disease (aGVHD). <i>Transplantation</i> , 2013, 95, 658-662.	0.5	18
420	Current data on IL-17 and Th17 cells and implications for graft versus host disease. <i>Einstein (Sao Paulo)</i> , Tj ETQq0 0,0 rgBT /Overlock 10	0.3	14
421	Pathobiology of graft-versus-host disease. , 0, , 297-310.		0



#	ARTICLE	IF	CITATIONS
422	The Role of Regulatory T Cells in the Biology of Graft Versus Host Disease. <i>Frontiers in Immunology</i> , 2013, 4, 163.	2.2	100
423	Lithothamnion muelleri Controls Inflammatory Responses, Target Organ Injury and Lethality Associated with Graft-versus-Host Disease in Mice. <i>Marine Drugs</i> , 2013, 11, 2595-2615.	2.2	12
424	Anaplerotic Metabolism of Alloreactive T Cells Provides a Metabolic Approach To Treat Graft-Versus-Host Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 298-307.	1.3	62
425	Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. <i>Bone Marrow Transplantation</i> , 2014, 49, 1162-1169.	1.3	30
426	The roles of myeloid-derived suppressor cells in transplantation. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1385-1394.	1.3	35
427	Nutritional Support in Adult Patients Undergoing Allogeneic Stem Cell Transplantation Following Myeloablative Conditioning. , 2014, , 1-15.		0
428	Progressive Proximal-to-Distal Reduction in Expression of the Tight Junction Complex in Colonic Epithelium of Virally-Suppressed HIV+ Individuals. <i>PLoS Pathogens</i> , 2014, 10, e1004198.	2.1	61
429	The Role of Dendritic Cells in Graft-Versus-Tumor Effect. <i>Frontiers in Immunology</i> , 2014, 5, 66.	2.2	14
430	Pretransplant C-reactive Protein as A Prognostic Marker in Allogeneic Stem Cell Transplantation. <i>Scandinavian Journal of Immunology</i> , 2014, 79, 206-213.	1.3	17
431	Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host disease. <i>Science Translational Medicine</i> , 2014, 6, 243ra87.	5.8	43
432	Total Body Irradiation and Cyclophosphamide Plus Antithymocyte Globulin Regimen Is Well Tolerated and Promotes Stable Engraftment as a Preparative Regimen before T Cell-Replete Haploidentical Transplantation for Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1176-1182.	2.0	21
433	Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. <i>BMC Infectious Diseases</i> , 2014, 14, 79.	1.3	23
434	Haploidentical Stem Cell Transplantation for Acute Leukemia Patients Who Experienced Early Relapse Within One Year After the First Transplantation. <i>Transplantation Proceedings</i> , 2014, 46, 3611-3615.	0.3	3
435	Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT. <i>Blood</i> , 2014, 124, 963-972.	0.6	62
436	Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. <i>British Journal of Haematology</i> , 2014, 167, 441-452.	1.2	106
437	Mast cells are crucial in the resistance against <i>Toxoplasma gondii</i> oral infection. <i>European Journal of Immunology</i> , 2014, 44, 2949-2954.	1.6	12
438	Oral Combined Therapy with Probiotics and Alloantigen Induces B Cell-Dependent Long-Lasting Specific Tolerance. <i>Journal of Immunology</i> , 2014, 192, 1928-1937.	0.4	21
439	Administration of Anti-CD20 mAb Is Highly Effective in Preventing but Ineffective in Treating Chronic Graft-Versus-Host Disease While Preserving Strong Graft-Versus-Leukemia Effects. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1089-1103.	2.0	30

#	ARTICLE	IF	CITATIONS
440	A paradoxical pattern of indoleamine 2,3-dioxygenase expression in the colon tissues of patients with acute graft-versus-host disease. <i>Experimental Hematology</i> , 2014, 42, 734-740.	0.2	7
441	Optimization of the therapeutic efficacy of human umbilical cord bloodâ€‘mesenchymal stromal cells in an NSG mouse xenograft model of graft-versus-host disease. <i>Cytotherapy</i> , 2014, 16, 298-308.	0.3	32
442	Siglec-Gâ€‘CD24 axis controls the severity of graft-versus-host disease in mice. <i>Blood</i> , 2014, 123, 3512-3523.	0.6	76
443	The biology of graft-versus-host disease: experimental systems instructing clinical practice. <i>Blood</i> , 2014, 124, 354-362.	0.6	153
445	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. <i>Blood</i> , 2015, 126, 1621-1628.	0.6	104
446	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 4085-4094.	0.6	101
447	Colonic complications following human bone marrow transplantation. <i>Journal of Coloproctology</i> , 2015, 35, 046-052.	0.1	2
448	Infusionâ€‘related febrile reaction after haploidentical stem cell transplantation in children is associated with higher rates of engraftment syndrome and acute graftâ€‘versusâ€‘host disease. <i>Pediatric Transplantation</i> , 2015, 19, 918-924.	0.5	11
449	Vascular abnormalities and biomarkers in patients with hematopoietic stem cell transplantation. <i>Journal of Hematopoietic Cell Transplantation</i> , 2015, 4, 57-65.	0.1	0
450	In vitro polyclonal activation of conventional Tâ€‘cells with a CD28 superagonist protects mice from acute graft versus host disease. <i>European Journal of Immunology</i> , 2015, 45, 1997-2007.	1.6	8
451	Administration of Hydrogen-Rich Saline in Mice with Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Medical Science Monitor</i> , 2015, 21, 749-754.	0.5	9
452	Systemic LPS Translocation Activates Cross-Presenting Dendritic Cells but Is Dispensable for the Breakdown of CD8+ T Cell Peripheral Tolerance in Irradiated Mice. <i>PLoS ONE</i> , 2015, 10, e0130041.	1.1	4
453	Attenuation of Hepatic Graft-versus-host Disease in Allogeneic Recipients of MyD88-deficient Donor Bone Marrow. <i>Immune Network</i> , 2015, 15, 125.	1.6	4
454	The Role of Intestinal Microbiota in Acute Graft-versus-Host Disease. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	0.9	26
455	Intestinal microbiota-related effects on graft-versus-host disease. <i>International Journal of Hematology</i> , 2015, 101, 428-437.	0.7	51
456	Lung parenchyma-derived IL-6 promotes IL-17Aâ€‘dependent acute lung injury after allogeneic stem cell transplantation. <i>Blood</i> , 2015, 125, 2435-2444.	0.6	73
457	Various Forms of Tissue Damage and Danger Signals Following Hematopoietic Stem-Cell Transplantation. <i>Frontiers in Immunology</i> , 2015, 6, 14.	2.2	42
458	Increased Bacterial Infections after Transfusion of Leukoreduced Non-Irradiated Blood Products in Recipients of Allogeneic Stem Cell Transplants after Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 526-530.	2.0	7

#	ARTICLE	IF	CITATIONS
459	Glucocorticoids attenuate acute graft-versus-host disease by suppressing the cytotoxic capacity of CD8 <sup>+</sup> T cells. <i>Journal of Pathology</i> , 2015, 235, 646-655.	2.1	33
460	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. <i>Molecular Immunology</i> , 2015, 67, 46-57.	1.0	100
461	ATM Gene Single Nucleotide Polymorphisms Predict Regimen-Related Gastrointestinal Toxicity in Patients Allografted after Reduced Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1136-1140.	2.0	5
462	Donor colonic CD103 <sup>+</sup> dendritic cells determine the severity of acute graft-versus-host disease. <i>Journal of Experimental Medicine</i> , 2015, 212, 1303-1321.	4.2	85
463	Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 559-565.	1.3	56
464	Rapid Functional Decline of Activated and Memory Graft-versus-Host-Responsive T Cells Encountering Host Antigens in the Absence of Inflammation. <i>Journal of Immunology</i> , 2015, 195, 1282-1292.	0.4	5
465	Valproic Acid Ameliorates Graft-versus-Host Disease by Downregulating Th1 and Th17 Cells. <i>Journal of Immunology</i> , 2015, 195, 1849-1857.	0.4	23
466	Mature T cell responses are controlled by microRNA-142. <i>Journal of Clinical Investigation</i> , 2015, 125, 2825-2840.	3.9	81
467	Cytokines in Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2015, 194, 4604-4612.	0.4	156
468	Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. <i>International Journal of Hematology</i> , 2015, 101, 438-451.	0.7	22
469	The Microbiome and Graft Versus Host Disease. <i>Current Stem Cell Reports</i> , 2015, 1, 39-47.	0.7	14
470	Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease. <i>Mucosal Immunology</i> , 2015, 8, 720-730.	2.7	106
471	State-of-the-art acute and chronic GVHD treatment. <i>International Journal of Hematology</i> , 2015, 101, 452-466.	0.7	72
472	Emerging Influence of the Intestinal Microbiota during Allogeneic Hematopoietic Cell Transplantation: Control the Gut and the Body Will Follow. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1360-1366.	2.0	42
473	A review of graft versus host disease. <i>Journal of Pediatric Intensive Care</i> , 2015, 03, 103-113.	0.4	0
474	Effect of the order of TBI and cyclophosphamide administration on the outcome of allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1476-1479.	1.3	1
475	IL-35 inhibits acute graft-versus-host disease in a mouse model. <i>International Immunopharmacology</i> , 2015, 29, 383-392.	1.7	11
476	Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation. <i>BMC Cancer</i> , 2015, 15, 607.	1.1	12

#	ARTICLE	IF	CITATIONS
477	ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. <i>Science Translational Medicine</i> , 2015, 7, 308ra160.	5.8	131
478	Toll-Like Receptor Polymorphisms in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 259-265.	2.0	11
479	Autophagy and haematopoietic stem cell transplantation. <i>Immunology and Cell Biology</i> , 2015, 93, 43-50.	1.0	8
480	IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects. <i>Leukemia</i> , 2015, 29, 939-946.	3.3	41
481	A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 242-249.	2.0	3
482	Biology of chronic graft-versus-host disease: Immune mechanisms and progress in biomarker discovery. <i>World Journal of Transplantation</i> , 2016, 6, 608.	0.6	30
483	Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. <i>JCI Insight</i> , 2016, 1, e86850.	2.3	43
484	Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. <i>Viruses</i> , 2016, 8, 85.	1.5	8
485	The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview. <i>Frontiers in Immunology</i> , 2016, 7, 333.	2.2	44
486	Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. <i>Journal of Clinical Investigation</i> , 2016, 126, 1413-1424.	3.9	355
487	Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease. <i>American Journal of Hematology</i> , 2016, 91, 931-937.	2.0	24
488	Discarded Human Thymus Is a Novel Source of Stable and Long-Lived Therapeutic Regulatory T Cells. <i>American Journal of Transplantation</i> , 2016, 16, 58-71.	2.6	84
489	Role of the intestinal mucosa in acute gastrointestinal GVHD. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 119-127.	0.9	6
490	Profile of Inflammation-Associated Proteins in Early Post-Transplant Samples of Patients After Allogeneic Hematopoietic Stem Cell Transplantation: a Preliminary Study. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 55-61.	1.0	3
491	Allospecific Tregs Expanded After Anergization Remain Suppressive in Inflammatory Conditions but Lack Expression of Gut-homing Molecules. <i>Molecular Therapy</i> , 2016, 24, 1126-1134.	3.7	1
492	Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 1855-1863.	0.8	100
493	Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 469-484.	0.5	4
494	Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1368-1375.	2.0	51

#	ARTICLE	IF	CITATIONS
495	Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1137-1141.	2.0	11
496	Ruxolitinib treatment for GvHD in patients with myelofibrosis. <i>Bone Marrow Transplantation</i> , 2016, 51, 1584-1587.	1.3	30
497	Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or mismatched donors. <i>Pediatric Hematology and Oncology</i> , 2016, 33, 347-358.	0.3	3
498	Immunosuppressive therapy alleviates murine cytomegalovirus recurrence by reducing TNF- $\alpha$ post cell transplantation with lethal GVHD. <i>Antiviral Research</i> , 2016, 133, 130-139.	1.9	4
502	Attenuation of graft-versus-host disease in NOD scid IL-2R $\beta$ (NSG) mice by ex vivo modulation of human CD4 <sup>+</sup> T cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016, 89, 803-815.	1.1	16
503	Role of the intestinal mucosa in acute gastrointestinal GVHD. <i>Blood</i> , 2016, 128, 2395-2402.	0.6	39
504	Pathology of Transplantation. , 2016, , .		1
505	Hematopoietic Stem Cell Transplantation. , 2016, , 401-449.		8
506	Evaluation of interleukin 12 and CD56 <sup>+</sup> lymphocyte cells in pediatric hematopoietic stem cell transplantation for early diagnosis of acute graft versus host disease. <i>Transplant Immunology</i> , 2016, 39, 25-29.	0.6	3
507	Cytosine-Phosphorothionate-Guanine Oligodeoxynucleotides Exacerbates Hemophagocytosis by Inducing Tumor Necrosis Factor- $\alpha$ Production in Mice after Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 627-636.	2.0	3
508	Soluble heat shock protein 70 members in patients undergoing allogeneic hematopoietic cell transplantation. <i>Transplant Immunology</i> , 2016, 36, 25-31.	0.6	5
509	Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 71-79.	2.0	11
510	Ferritin as an early marker of graft rejection after allogeneic hematopoietic stem cell transplantation in pediatric patients. <i>Annals of Hematology</i> , 2016, 95, 311-323.	0.8	13
511	A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 410-417.	1.3	37
512	MyD88 in donor bone marrow cells is critical for protection from acute intestinal graft-vs.-host disease. <i>Mucosal Immunology</i> , 2016, 9, 730-743.	2.7	14
513	Simvastatin ameliorates graft-vs-host disease by regulating angiopoietin-1 and angiopoietin-2 in a murine model. <i>Leukemia Research</i> , 2017, 55, 49-54.	0.4	6
514	Association between C-reactive protein levels in the first 1-3 days post-transplant and allogeneic immune reactions. <i>Biomarkers in Medicine</i> , 2017, 11, 117-124.	0.6	1
515	Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation. <i>Onc Immunology</i> , 2017, 6, e1284721.	2.1	28

#	ARTICLE	IF	CITATIONS
516	Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome. <i>Blood</i> , 2017, 129, 2172-2185.	0.6	63
517	Citrulline and Monocyte-Derived Macrophage Reactivity before Conditioning Predict Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 913-921.	2.0	13
518	Renal Clearable Luminescent WSe <sub>2</sub> for Radioprotection of Nontargeted Tissues during Radiotherapy. <i>Particle and Particle Systems Characterization</i> , 2017, 34, 1700035.	1.2	24
519	Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1555-1566.	2.0	21
520	Eomesodermin promotes the development of type 1 regulatory T (T <sub>R</sub> 1) cells. <i>Science Immunology</i> , 2017, 2, .	5.6	118
521	GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity. <i>Blood</i> , 2017, 129, 630-642.	0.6	32
522	Harnessing bone marrow resident regulatory T cells to improve allogeneic stem cell transplant outcomes. <i>International Journal of Hematology</i> , 2017, 105, 153-161.	0.7	8
523	Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes. <i>Oncolmunology</i> , 2017, 6, e1356152.	2.1	28
524	A20 deletion in T cells modulates acute graft-versus-host disease in mice. <i>European Journal of Immunology</i> , 2017, 47, 1982-1988.	1.6	9
525	Dynamics of M1 macrophages in oral mucosal lesions during the development of acute graft-versus-host disease in rats. <i>Clinical and Experimental Immunology</i> , 2017, 190, 315-327.	1.1	10
526	CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy. <i>Experimental and Molecular Medicine</i> , 2017, 49, e360-e360.	3.2	8
527	Differential T cell subsets and cytokine profile between steady-state and G-CSF-primed bone marrow and its association with graft-versus-host disease. <i>Leukemia Research</i> , 2017, 63, 47-52.	0.4	2
528	STAT3 Expression in Host Myeloid Cells Controls Graft-versus-Host Disease Severity. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1622-1630.	2.0	7
529	Association between single nucleotide polymorphisms of tumor necrosis factor gene and grade II-IV acute GvHD: a systematic review and meta-analysis. <i>Bone Marrow Transplantation</i> , 2017, 52, 1423-1427.	1.3	4
530	Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E5881-E5890.	3.3	58
531	6-Shogaol ameliorates injury to the intestinal mucosa and increases survival after high-dose abdominal irradiation. <i>Journal of Functional Foods</i> , 2017, 36, 63-71.	1.6	12
532	B Lymphocyte Chemoattractant (CXCL13) Is an Indicator of Acute Gastrointestinal GVHD in Murine Model. <i>Inflammation</i> , 2017, 40, 1678-1687.	1.7	3
533	HIF-1 inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. <i>Journal of Translational Medicine</i> , 2017, 15, 28.	1.8	19

#	ARTICLE	IF	CITATIONS
534	Pre-Transplantation Blockade of TNF- $\alpha$ -Mediated Oxygen Species Accumulation Protects Hematopoietic Stem Cells. <i>Stem Cells</i> , 2017, 35, 989-1002.	1.4	23
535	Cutaneous manifestations of graft-versus-host disease: role of the dermatologist. <i>International Journal of Dermatology</i> , 2017, 56, 131-140.	0.5	28
536	Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation. <i>American Journal of Hematology</i> , 2017, 92, 171-178.	2.0	38
537	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	2.3	166
538	TLR/MyD88-mediated Innate Immunity in Intestinal Graft-versus-Host Disease. <i>Immune Network</i> , 2017, 17, 144.	1.6	26
539	Pathophysiology of GvHD and Other HSCT-Related Major Complications. <i>Frontiers in Immunology</i> , 2017, 8, 79.	2.2	166
540	Protection of Mice from Acute Graft-versus-Host Disease Requires CD28 Co-stimulation on Donor CD4+ Foxp3+ Regulatory T Cells. <i>Frontiers in Immunology</i> , 2017, 8, 721.	2.2	1
541	Is It Time to Reconsider the Lipopolysaccharide Paradigm in Acute Graft-Versus-Host Disease?. <i>Frontiers in Immunology</i> , 2017, 8, 952.	2.2	9
542	Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease. <i>PLoS ONE</i> , 2017, 12, e0183284.	1.1	13
543	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 222-234.	8.2	82
544	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	1.7	38
545	IL-2 and Beyond in Cancer Immunotherapy. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 45-68.	0.5	83
546	Involvement of TLR3-Dependent PGES Expression in Immunosuppression by Human Bone Marrow Mesenchymal Stem Cells. <i>Stem Cell Reviews and Reports</i> , 2018, 14, 286-293.	5.6	18
547	MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. <i>Journal of Immunology</i> , 2018, 200, 4170-4179.	0.4	24
548	Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 242-251.	2.0	70
549	A critical role for donor-derived IL-22 in cutaneous chronic GVHD. <i>American Journal of Transplantation</i> , 2018, 18, 810-820.	2.6	45
550	New Insights into Graft-Versus-Host Disease and Graft Rejection. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 219-245.	9.6	55
551	Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80. <i>Frontiers in Immunology</i> , 2018, 9, 3061.	2.2	28

#	ARTICLE	IF	CITATIONS
552	IL-17C Mitigates Murine Acute Graft-vs.-Host Disease by Promoting Intestinal Barrier Functions and Treg Differentiation. <i>Frontiers in Immunology</i> , 2018, 9, 2724.	2.2	5
553	Notch Signaling in Graft-Versus-Host Disease. , 2018, , 175-197.		0
554	Cucurbitacin E ameliorates acute graft-versus-host disease by modulating Th17 cell subsets and inhibiting STAT3 activation. <i>Immunology Letters</i> , 2018, 203, 62-69.	1.1	9
555	Stabilization of Foxp3 by Targeting JAK2 Enhances Efficacy of CD8 Induced Regulatory T Cells in the Prevention of Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2018, 201, 2812-2823.	0.4	26
556	During acute graft versus host disease CD28 deletion in donor CD8+, but not CD4+, T cells maintain antileukemia responses in mice. <i>European Journal of Immunology</i> , 2018, 48, 2055-2067.	1.6	2
557	The impact of cytokine gene polymorphisms on the outcome of HLA matched sibling hematopoietic stem cell transplantation. <i>Cytokine</i> , 2018, 110, 404-411.	1.4	8
558	Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2190-2196.	2.0	10
559	Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 12-18.	2.0	4
560	MAGIC biomarkers of acute graft-versus-host disease: Biology and clinical application. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 101111.	0.7	13
561	Caspase-11 signaling enhances graft-versus-host disease. <i>Nature Communications</i> , 2019, 10, 4044.	5.8	19
562	Cytokines in GVHD and GVL. , 2019, , 293-322.		2
563	Chemokines and Graft-Versus-Host Disease. , 2019, , 323-347.		0
564	Altered donor P2X7 activity in human leukocytes correlates with P2RX7 genotype but does not affect the development of graft-versus-host disease in humanised mice. <i>Purinergic Signalling</i> , 2019, 15, 177-192.	1.1	17
565	Inflammatory Cytokine Networks in Gastrointestinal Tract Graft vs. Host Disease. <i>Frontiers in Immunology</i> , 2019, 10, 163.	2.2	29
566	The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease. <i>Blood</i> , 2019, 134, 2139-2148.	0.6	55
567	IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling. <i>Blood</i> , 2019, 134, 2092-2106.	0.6	29
568	FL/GCSF/AMD3100-mobilized Hematopoietic Stem Cells Induce Mixed Chimerism With Nonmyeloablative Conditioning and Transplantation Tolerance. <i>Transplantation</i> , 2019, 103, 1360-1371.	0.5	2
569	Associations between febrile neutropenia-related parameters and the risk of acute GVHD or non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 707-716.	1.3	3



#	ARTICLE	IF	CITATIONS
570	Notch inhibition enhances graft-versus-leukemia while reducing graft-versus-host disease. <i>European Journal of Pharmacology</i> , 2019, 843, 226-232.	1.7	6
571	Hybrid resistance to parental bone marrow grafts in nonlethally irradiated mice. <i>American Journal of Transplantation</i> , 2019, 19, 591-596.	2.6	10
572	Host MyD88 signaling protects against acute graft-versus-host disease after allogeneic bone marrow transplantation. <i>Clinical and Experimental Immunology</i> , 2019, 195, 121-131.	1.1	4
573	Radiation and host retinoic acid signaling promote the induction of gut-homing donor T cells after allogeneic hematopoietic stem cell transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 64-74.	2.6	2
574	Myeloid differentiation factor 88 signaling in donor T cells accelerates graft-versus-host disease. <i>Haematologica</i> , 2020, 105, 226-234.	1.7	12
575	Tyrosine supplement ameliorates murine aGVHD by modulation of gut microbiome and metabolome. <i>EBioMedicine</i> , 2020, 61, 103048.	2.7	17
576	The safety and effectiveness of genetically corrected iPSCs derived from $\beta^2$ -thalassaemia patients in nonmyeloablative $\beta^2$ -thalassaemic mice. <i>Stem Cell Research and Therapy</i> , 2020, 11, 288.	2.4	4
577	Short chain fatty acids: Postbiotics/metabolites and graft versus host disease colitis. <i>Seminars in Hematology</i> , 2020, 57, 1-6.	1.8	24
578	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. <i>Annals of Internal Medicine</i> , 2020, 172, 229.	2.0	157
579	The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation</i> , 2020, 104, 2507-2515.	0.5	5
580	CD4+CD8+ T-Lymphocytes in Xenogeneic and Human Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2020, 11, 579776.	2.2	9
581	Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT. <i>Frontiers in Immunology</i> , 2020, 11, 593863.	2.2	21
582	Treating From the Inside Out: Relevance of Fecal Microbiota Transplantation to Counteract Gut Damage in GVHD and HIV Infection. <i>Frontiers in Medicine</i> , 2020, 7, 421.	1.2	17
583	Carnitine Profile Changes in Pediatric Hematopoietic Stem Cell Transplant: New Role for Carnitine?. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e321-e327.	0.3	1
584	Steroid-refractory acute graft-versus-host disease graded III-IV in pediatric patients. A mono-institutional experience with a long-term follow-up. <i>Pediatric Transplantation</i> , 2020, 24, e13806.	0.5	2
585	Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	89
586	Donor T <sub>H</sub> 17 cell depletion with fludarabine reduces graft-versus-host disease signs and improves survival after intestinal transplantation - an experimental study. <i>Transplant International</i> , 2020, 33, 1302-1311.	0.8	4
587	Cytokines and costimulation in acute graft-versus-host disease. <i>Blood</i> , 2020, 136, 418-428.	0.6	66

#	ARTICLE	IF	CITATIONS
588	Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 8031-8044.	1.6	23
589	Insights into the role of the JAK/STAT signaling pathway in graft-versus-host disease. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072091448.	1.1	19
590	Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. <i>Blood Advances</i> , 2020, 4, 2317-2324.	2.5	1
591	Prevention of acute graft-versus-host-disease by Withaferin a via suppression of AKT/mTOR pathway. <i>International Immunopharmacology</i> , 2020, 84, 106575.	1.7	8
592	Ruxolitinib for the treatment of graft-versus-host disease. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 347-359.	1.3	15
593	GCNT1-Mediated O-Glycosylation of the Sialomucin CD43 Is a Sensitive Indicator of Notch Signaling in Activated T Cells. <i>Journal of Immunology</i> , 2020, 204, 1674-1688.	0.4	17
594	Paving the way towards universal treatment with allogenic T cells. <i>Immunologic Research</i> , 2020, 68, 63-70.	1.3	20
595	Berberine combined with cyclosporine A alleviates acute graft-versus-host disease in murine models. <i>International Immunopharmacology</i> , 2020, 81, 106205.	1.7	6
596	Continuous pre- and post-transplant exposure to a disease-associated gut microbiome promotes hyper-acute graft-versus-host disease in wild-type mice. <i>Gut Microbes</i> , 2020, 11, 754-770.	4.3	17
597	Mitochondrial transfer from MSCs to T cells induces Treg differentiation and restricts inflammatory response. <i>EMBO Reports</i> , 2020, 21, e48052.	2.0	129
598	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. <i>Blood</i> , 2021, 137, 1090-1103.	0.6	8
599	Retinoic acid-responsive CD8 effector T cells are selectively increased in IL-23-rich tissue in gastrointestinal GVHD. <i>Blood</i> , 2021, 137, 702-717.	0.6	6
600	Graft-Versus-Host Disease (GvHD) Prophylaxis. , 2021, , 153-186.		0
601	Functional Contributions of Antigen Presenting Cells in Chronic Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2021, 12, 614183.	2.2	4
602	Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis. <i>Annals of Hematology</i> , 2021, 100, 969-978.	0.8	0
603	Case Series: Development of Polyps as a Late Effect After Total Body Irradiation-based Hematopoietic Cell Transplantation in Children With High-risk Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e1159-e1163.	0.3	2
604	The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD). <i>Journal of Clinical Medicine</i> , 2021, 10, 2050.	1.0	23
605	IL-17-producing T cells ameliorate intestinal acute graft-versus-host disease by recruitment of Gr-1+CD11b+ myeloid-derived suppressor cells. <i>Bone Marrow Transplantation</i> , 2021, 56, 2389-2399.	1.3	1

#	ARTICLE	IF	CITATIONS
606	DNAM-1 regulates Foxp3 expression in regulatory T cells by interfering with TIGIT under inflammatory conditions. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	24
607	LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease via Skewing Allogeneic T Cells Polarization Towards Treg Cells. Frontiers in Immunology, 2021, 12, 647894.	2.2	3
608	Advances in Intestinal Barrier Preservation and Restoration in the Allogeneic Hematopoietic Cell Transplantation Setting. Journal of Clinical Medicine, 2021, 10, 2508.	1.0	10
609	A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. PLoS ONE, 2021, 16, e0252995.	1.1	3
610	Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease. Frontiers in Immunology, 2021, 12, 705342.	2.2	4
611	Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease. HemaSphere, 2021, 5, e581.	1.2	10
612	Native Spleen Preservation During Visceral Transplantation Inhibits Graft-Versus-Host-Disease Development. Annals of Surgery, 2023, 277, e235-e244.	2.1	5
613	Compound A Increases Cell Infiltration in Target Organs of Acute Graft-versus-Host Disease (aGVHD) in a Mouse Model. Molecules, 2021, 26, 4237.	1.7	0
614	Early remodeling of the colonic mucosa after allogeneic hematopoietic stem cells transplantation: An open-label controlled pilot study on 19 patients. United European Gastroenterology Journal, 2021, 9, 955-963.	1.6	3
615	The Pathophysiology and Treatment of Graft-Versus-Host Disease: Lessons Learnt From Animal Models. Frontiers in Immunology, 2021, 12, 715424.	2.2	15
616	Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control. Frontiers in Cell and Developmental Biology, 2021, 9, 737880.	1.8	7
617	Donor bone marrow-derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice. Blood, 2022, 139, 1389-1408.	0.6	14
618	Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-Versus-Host Disease in Humans. Frontiers in Immunology, 2021, 12, 700857.	2.2	5
619	Platelet and Red Blood Cell Transfusions and Risk of Acute Graft-versus-Host Disease after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 866.e1-866.e9.	0.6	2
620	First Multimodal, Three-Dimensional, Image-Guided Total Marrow Irradiation Model for Preclinical Bone Marrow Transplantation Studies. International Journal of Radiation Oncology Biology Physics, 2021, 111, 671-683.	0.4	8
621	Graft Versus Host Disease: Management of Acute and Chronic Disease. Organ and Tissue Transplantation, 2021, , 365-393.	0.0	0
622	The Pathophysiology of Graft-Vs.-Host Disease. , 0, , 353-368.		18
623	Overview of Hematopoietic Cell Transplantation Immunology. , 0, , 16-30.		1

#	ARTICLE	IF	CITATIONS
624	The Yin and Yang of Adaptive Immunity in Allogeneic Hematopoietic Cell Transplantation: Donor Antigen-Presenting Cells Can Either Augment or Inhibit Donor T Cell Alloreactivity. , 2007, 590, 69-87.		3
625	Endothelial and Epithelial Barriers in Graft-Versus-Host Disease. Advances in Experimental Medicine and Biology, 2013, 763, 105-131.	0.8	9
626	Nutritional Support in Adult Patients Undergoing Allogeneic Stem Cell Transplantation Following Myeloablative Conditioning. , 2015, , 593-605.		3
627	Non-Myeloablative Hematopoietic Stem Cell Transplantation (NST) in the Treatment of Human Malignancies: From Animal Models to Clinical Practice. Cancer Treatment and Research, 2002, 110, 113-136.	0.2	7
628	Adoptive Immunotherapy Using Donor Leukocyte Infusions to Treat Relapsed Hematologic Malignancies after Allogeneic Bone Marrow Transplantation. Cancer Treatment and Research, 1999, 101, 233-266.	0.2	2
629	Non Myeloablative "Mini Transplants": Cancer Treatment and Research, 1999, , 97-108.	0.2	37
630	Nonmyeloablative Transplantation. , 2004, , 469-484.		1
631	Acute Graft-vs-Host Disease. , 2004, , 159-184.		2
632	Pathophysiology of Acute Graft-versus-Host Disease. , 2008, , 563-588.		1
633	Treatment of Acute Graft-vs-Host Disease. , 2010, , 747-765.		2
634	Cellular Therapy for Hematology Malignancies: Allogeneic Hematopoietic Stem Transplantation, Graft-Versus-Host Disease, and Graft Versus Leukemia Effects. , 2012, , 303-366.		1
635	Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. British Journal of Haematology, 2000, 111, 18-29.	1.2	179
636	Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Current Opinion in Oncology, 1999, 11, 87.	1.1	67
637	ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE IN A SYNGENEIC BONE MARROW TRANSPLANT RECIPIENT. Transplantation, 1998, 66, 1251-1253.	0.5	11
638	PRETRANSPLANT CHEMOTHERAPY REDUCES INFLAMMATORY CYTOKINE PRODUCTION AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION. Transplantation, 1999, 67, 1478-1480.	0.5	25
641	Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in T regulatory cells. JCI Insight, 2019, 4, .	2.3	58
643	PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease. JCI Insight, 2020, 5, .	2.3	25
644	Siglec-G represses DAMP-mediated effects on T cells. JCI Insight, 2017, 2, .	2.3	37

#	ARTICLE	IF	CITATIONS
645	Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHD. JCI Insight, 2017, 2, .	2.3	12
646	Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. Journal of Clinical Investigation, 2002, 109, 1249-1256.	3.9	76
647	Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. Journal of Clinical Investigation, 2002, 109, 1335-1344.	3.9	162
648	Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function. Journal of Clinical Investigation, 2001, 107, 1365-1373.	3.9	104
649	LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. Journal of Clinical Investigation, 2001, 107, 1581-1589.	3.9	258
650	Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. Journal of Clinical Investigation, 2002, 109, 1335-1344.	3.9	97
651	Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model. Journal of Clinical Investigation, 2003, 112, 1880-1886.	3.9	63
652	NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. Journal of Clinical Investigation, 2005, 115, 3093-3103.	3.9	114
653	Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.. Journal of Clinical Investigation, 1998, 102, 115-123.	3.9	256
654	Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.. Journal of Clinical Investigation, 1998, 102, 1742-1748.	3.9	201
655	Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. Journal of Clinical Investigation, 2010, 120, 3855-3868.	3.9	52
656	Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.. Journal of Clinical Investigation, 1998, 102, 1882-1891.	3.9	306
657	Differential roles of IL-1 and TNF-Î± on graft-versus-host disease and graft versus leukemia. Journal of Clinical Investigation, 1999, 104, 459-467.	3.9	229
658	IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. Journal of Clinical Investigation, 1999, 104, 317-325.	3.9	159
659	CSF-1-dependent donor-derived macrophages mediate chronic graft-versus-host disease. Journal of Clinical Investigation, 2014, 124, 4266-4280.	3.9	173
660	A colitogenic memory CD4+ T cell population mediates gastrointestinal graft-versus-host disease. Journal of Clinical Investigation, 2016, 126, 3541-3555.	3.9	30
661	Differential requirements for myeloid leukemia IFN-Î³ conditioning determine graft-versus-leukemia resistance and sensitivity. Journal of Clinical Investigation, 2017, 127, 2765-2776.	3.9	18
662	Cytokine mediators of chronic graft-versus-host disease. Journal of Clinical Investigation, 2017, 127, 2452-2463.	3.9	74

#	ARTICLE	IF	CITATIONS
663	Host Reactive Donor T Cells Are Associated With Lung Injury After Experimental Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1998, 92, 2571-2580.	0.6	18
664	Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft-Versus-Host Disease. <i>Blood</i> , 1999, 94, 825-831.	0.6	8
666	The Pathophysiology of Graft-vs.-Host Disease. , 2004, , 1-34.		4
667	Natural Killer Cell Mediated Missing-Self Recognition Can Protect Mice from Primary Chronic Myeloid Leukemia In Vivo. <i>PLoS ONE</i> , 2011, 6, e27639.	1.1	14
668	Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD). <i>PLoS ONE</i> , 2014, 9, e88868.	1.1	25
669	Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology. <i>PLoS Pathogens</i> , 2016, 12, e1005398.	2.1	92
670	The glucocorticoid receptor in recipient cells keeps cytokine secretion in acute graft-versus-host disease at bay. <i>Oncotarget</i> , 2018, 9, 15437-15450.	0.8	14
671	Innate Immune Determinants of Graft-Versus-Host Disease and Bidirectional Immune Tolerance in Allogeneic Transplantation. <i>OBM Transplantation</i> , 2019, 3, 1-1.	0.2	2
672	Kinetics of IFN- $\gamma$ and IL-17 Production by CD4 and CD8 T Cells during Acute Graft-versus-Host Disease. <i>Immune Network</i> , 2014, 14, 89.	1.6	10
673	Decreased Risk of Acute Graft-versus-Host Disease Using Reduced Intensity Conditioning Compared to Myeloablative Conditioning is Independent of Donor-Recipient T-cell Chimerism. <i>Journal of Transplantation Technologies &amp; Research</i> , 2014, 04, .	0.1	1
674	Enhancement of Graft-versus-leukemia Effects by Mesenchymal Stem Cells in Mixed Chimerism after a Murine Non-myeloablative Hematopoietic Stem Cell Transplantation. <i>The Korean Journal of Hematology</i> , 2008, 43, 219.	0.7	2
675	Hydrogen, a potential safeguard for graft-versus-host disease and graft ischemia-reperfusion injury?. <i>Clinics</i> , 2016, 71, 544-549.	0.6	9
676	Cyclosporine A but Not Corticosteroids Support Efficacy of Ex Vivo Expanded, Adoptively Transferred Human Tregs in GvHD. <i>Frontiers in Immunology</i> , 2021, 12, 716629.	2.2	4
677	T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor. <i>Frontiers in Immunology</i> , 2021, 12, 761448.	2.2	42
678	New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD). <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 761-771.	1.5	10
679	Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease. <i>Frontiers in Oncology</i> , 2021, 11, 760789.	1.3	7
680	Experimental Animal Models in the Study of GVL Reactions. , 2000, , .		0
681	Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis. <i>Blood</i> , 2000, 96, 1836-1843.	0.6	14

#	ARTICLE	IF	CITATIONS
682	ALLOJENE K K K H CRE TRANSPLANTASYONU SONRASI Th1/Th2 S T O K NLER VE SOLUBL ADEZYON MOLEKULLER: K K H CRE KAYNAZI VE DALTEPARAN KULLANIMININ ETKELER. Ankara Üniversitesi Tıp Fakültesi Mecmuası, 2001, 54, 1.	0.7	1
683	Pathogenic mechanisms of Acute Graft versus Host Disease. Revista Brasileira De Hematologia E Hemoterapia, 2002, 24, .	0.7	1
684	In Vivo Models for the Study of Graft-vs-Host Disease and Graft-vs-Tumor Effects. , 2003, , 373-386.		0
685	Pathophysiology of Lung Injury After Hematopoietic Stem Cell Transplantation. , 2004, , 271-295.		0
686	Pathophysiology of Acute Graft-vs-Host Disease. , 2004, , 135-157.		1
687	Chemokines and Graft-vs.-Host Disease. , 2004, , 125-153.		0
688	Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation with Non-Myeloablative Conditioning: Experiences at a Single Center. The Korean Journal of Hematology, 2006, 41, 92.	0.7	0
689	Therapeutic Effect of CXCR3-Expressing Regulatory T Cells on Liver and Intestinal Damages in a Murine Acute GVHD Model.. Blood, 2007, 110, 2161-2161.	0.6	0
690	Lung Injury after Hematopoietic Stem Cell Transplantation. , 2008, , 495-536.		0
691	Adoptive Transfer of T-Bodies: Toward an Effective Cancer Immunotherapy. , 2009, , 285-299.		0
693	In Vivo Models of Allogeneic Hematopoietic Stem Cell Transplantation. , 2010, , 789-805.		0
694	Stem Cell Transplantation for Non-Hodgkin's Lymphomas. , 2013, , 371-402.		0
695	Macrophage Classical Activation. , 0, , 301-323.		0
696	Granulocyte Colony-Stimulating Factor Mobilized Allogeneic Stem Cell Transplantation Maintains Graft-Versus-Leukemia Effects Through a Perforin-Dependent Pathway While Preventing Graft-Versus-Host Disease. Blood, 1999, 93, 4071-4078.	0.6	4
697	Graft Versus Host Disease (GVHD). , 2016, , 429-449.		0
698	Cell Death and Skin Disease. , 2017, , 201-217.		0
699	Allogeneic haematopoietic stem cell transplantation. , 2019, , 257-266.		0
700	Graft Versus Host Disease: Management of Acute and Chronic Disease. Organ and Tissue Transplantation, 2021, , 1-30.	0.0	0

#	ARTICLE	IF	CITATIONS
701	Graft-versus-host disease. , 2020, , 114-117.e1.		1
703	Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2002, 109, 1249-1256.	3.9	36
704	Does Total Body Irradiation Have a Favorable Impact on Thrombocyte Engraftment as per Neutrophil Engraftment in Allogeneic Stem Cell Transplantation?. <i>Cureus</i> , 2021, 13, e19462.	0.2	1
705	CCL8 deficiency in the host abrogates early mortality of acute graft-versus-host disease in mice with dysregulated IL-6 expression. <i>Experimental Hematology</i> , 2022, 106, 47-57.	0.2	2
706	Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft Versus Host Disease. <i>Frontiers in Immunology</i> , 2021, 12, 779076.	2.2	2
707	A Polymorphism of Bactericidal/Permeability-Increasing Protein Affects Its Neutralization Efficiency towards Lipopolysaccharide. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1324.	1.8	5
708	Mouse models of graft-versus-host disease. <i>Methods in Cell Biology</i> , 2022, 168, 41-66.	0.5	1
709	High-density lipoprotein infusion protects from acute graft-versus-host disease in experimental allogeneic hematopoietic cell transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 1350-1361.	2.6	6
710	mTOR Signaling Regulates the Development and Therapeutic Efficacy of PMN-MDSCs in Acute GVHD. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 741911.	1.8	2
711	Modeling acute graft-versus-host disease (aGVHD) in murine bone marrow transplantation (BMT) models with MHC disparity. <i>Methods in Cell Biology</i> , 2022, 168, 19-39.	0.5	1
712	Human Monocyte-Derived Suppressor Cell Supernatant Induces Immunoregulatory Effects and Mitigates xenoGvHD. <i>Frontiers in Immunology</i> , 2022, 13, 827712.	2.2	2
722	Nutritional Support of Hematopoietic Cell Recipients. , 0, , 883-893.		1
724	Aryl hydrocarbon receptor-targeted therapy for CD4+ T cell-mediated idiopathic pneumonia syndrome in mice. <i>Blood</i> , 2022, 139, 3325-3339.	0.6	6
725	Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. <i>Blood Advances</i> , 2022, 6, 3707-3715.	2.5	9
727	Bone marrow transplantation induces changes in the gut microbiota that chronically increase the cytokine response pattern of splenocytes. <i>Scientific Reports</i> , 2022, 12, 6883.	1.6	2
729	Reversing radiation-induced immunosuppression using a new therapeutic modality. <i>Life Sciences in Space Research</i> , 2022, 35, 127-139.	1.2	15
730	Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-versus-host disease. <i>Mucosal Immunology</i> , 2022, 15, 605-619.	2.7	8
731	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 681-693.	0.6	13



#	ARTICLE	IF	CITATIONS
732	Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2022, 6, 4098-4106.	2.5	9
733	Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
735	Insights into mechanisms of graft-versus-host disease through humanised mouse models. <i>Bioscience Reports</i> , 2022, 42, .	1.1	7
736	Induction of syngeneic graft-versus-host disease in LPS hyporesponsive C3H/HeJ mice. <i>Journal of Leukocyte Biology</i> , 2001, 70, 873-880.	1.5	9
737	Glucocorticoid and glycolysis inhibitors cooperatively abrogate acute graft-versus-host disease. <i>Science China Life Sciences</i> , 2023, 66, 528-544.	2.3	3
738	Disturbances in microbial skin recolonization and cutaneous immune response following allogeneic stem cell transfer. <i>Leukemia</i> , 2022, 36, 2705-2714.	3.3	3
739	Enforced mesenchymal stem cell tissue colonization counteracts immunopathology. <i>Npj Regenerative Medicine</i> , 2022, 7, .	2.5	6
741	Controversies and expectations for the prevention of GVHD: A biological and clinical perspective. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
742	Milestones in acute GVHD pathophysiology. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
743	Long-term follow up of patients with hematological malignancies treated with total body irradiation using intensity modulated radiation therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
744	EPC infusion ameliorates acute graft-versus-host disease-related endothelial injury after allogeneic bone marrow transplantation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
745	Impact of total marrow/lymphoid irradiation dose to the intestine on graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for hematologic malignancies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
746	Ex Vivo Anti-CD3 Antibody-Activated Donor T Cells Have a Reduced Ability to Cause Lethal Murine Graft-Versus-Host Disease but Retain Their Ability to Facilitate Alloengraftment. <i>Journal of Immunology</i> , 1998, 161, 2610-2619.	0.4	38
747	Visualization, Fate, and Pathogenicity of Antigen-Specific CD8+ T Cells in the Graft-Versus-Host Reaction. <i>Journal of Immunology</i> , 1999, 163, 4780-4787.	0.4	14
748	Role of Immunoregulatory Donor T Cells in Suppression of Graft-Versus-Host Disease Following Donor Leukocyte Infusion Therapy. <i>Journal of Immunology</i> , 1999, 163, 6479-6487.	0.4	48
749	Insights and strategies to promote immune tolerance in allogeneic hematopoietic stem cell transplantation recipients. , 2023, , 329-360.		0
750	Cytokine profiling during conditioning in haploidentical stem cell transplantation and its prognostic impact on early transplant outcomes. <i>Transplant Immunology</i> , 2023, 78, 101830.	0.6	1
751	Advantages of Higher Busulfan Dose Intensity in Fludarabine-Combined Conditioning for Patients with Acute Myeloid Leukemia Undergoing Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2023, , .	0.6	0

#	ARTICLE	IF	CITATIONS
752	Enforced gut homing of murine regulatory T cells reduces early graft-versus-host disease severity. American Journal of Transplantation, 2023, , .	2.6	1
753	Impact of oral microbiota on pathophysiology of GVHD. Frontiers in Immunology, 0, 14, .	2.2	2
754	Effect of lethal total body irradiation on bone marrow chimerism, acute graft-versus-host disease, and tumor engraftment in mouse models: impact of different radiation techniques using low- and high-energy X-rays. Strahlentherapie Und Onkologie, 0, , .	1.0	1
755	The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation. International Journal of Molecular Sciences, 2023, 24, 5764.	1.8	3
756	Total marrow irradiation for second allogeneic hematopoietic stem cell transplantation in patients with advanced acute leukemia. Transplantation and Cellular Therapy, 2023, , .	0.6	0